CD206⁺IL-4Rα⁺ MACROPHAGES ARE DRIVERS OF ADVERSE CARDIAC REMODELING IN ISCHEMIC CARDIOMYOPATHY

Qiongxin Wang, PhD;^{1,2,3} Mohamed Ameen Ismahil, PhD;^{1,3} Yujie Zhu, MD, PhD;^{1,3} Gregg Rokosh, PhD;^{1,3} Tariq Hamid, PhD;^{1,3} Guihua Zhou, MD, PhD;¹ Steven M. Pogwizd, MD;¹ Sumanth D. Prabhu, MD^{1,3}

¹Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, AL
 ²Department of Cardiology, Zhongnan Hospital of Wuhan University, Wuhan, China,
 ³Division of Cardiology, Department of Medicine, Washington University School of Medicine, St.
 Louis, MO

Running title: Alternatively activated macrophages promote adverse cardiac remodeling

Corresponding Author:

Sumanth D. Prabhu, MD Lewin Distinguished Professor and Chief Division of Cardiology Washington University School of Medicine 660 S. Euclid Ave CB 8086 St. Louis, MO 63110 Tel: 314-362-8908 Fax: 314-454-5550 Email: prabhu@wustl.edu

NONSTANDARD ABBREVIATIONS AND ACRONYMS

LV left	ventricular
---------	-------------

MI	myocardial infarction
HF	heart failure
EF	ejection fraction
EDV	end-diastolic volume
ESV	end-systolic volume
LVAD	left ventricular assist device
BMDM	bone marrow-derived macrophage
cMSC	cardiac mesenchymal stem cell
ASO	antisense oligonucleotide
CCR2	C-C motif chemokine receptor 2
IL	interleukin
TGF-β	tumor growth factor-β
Arg1	arginase 1
FIZZ	found in inflammatory zone
Col	collagen
PDGF	platelet-derived growth factor
α-SMA	α -smooth muscle actin
NICD	Notch intracellular domain

1 ABSTRACT

BACKGROUND: Cardiac CD206⁺ macrophages expand acutely after myocardial infarction (MI)
to promote wound healing; however, their role in chronic heart failure (HF) is unknown. We
tested the hypothesis that cardiac CD206⁺ macrophages expressing interleukin(IL)-4Rα are key
drivers of adverse left ventricular (LV) remodeling in HF.

METHODS AND RESULTS: Adult male C57BL/6 mice underwent non-reperfused MI to induce 6 HF, or sham operation, and cardiac macrophages were profiled using flow cytometry. As 7 compared to sham, CD206⁺ macrophages steadily expanded in post-MI hearts during LV 8 remodeling, such that at 8 w post-MI they comprised ~85% of all macrophages. These 9 macrophages were robustly proliferative and predominantly C-C motif chemokine receptor 10 (CCR2)⁻ and major histocompatibility complex (MHC)II^{hi}, with >90% of CD206⁺CCR2⁻ 11 macrophages expressing the resident macrophage marker LYVE-1. CD206⁺ macrophage 12 abundance correlated with LV dysfunction and fibrosis. Nearly half of CD206⁺ macrophages 13 expressed IL-4R α , and the majority of CD206⁺IL-4R α ⁺ macrophages co-expressed the pro-14 fibrotic protein found in inflammatory zone (FIZZ)1. IL-4-polarized bone marrow derived CD206⁺ 15 16 macrophages also exhibited marked upregulation of FIZZ1 and induced FIZZ1-dependent myofibroblast differentiation of cardiac mesenchymal stem cells (cMSCs), in part related to DLL-17 4/Jagged1-Notch1 signaling. Intramyocardial adoptive transfer of M[IL-4], but not M[IL-10], 18 CD206⁺ macrophages to naïve mice, induced progressive LV remodeling over 4 weeks, 19 increasing fibrosis, cardiomyocyte hypertrophy, and apoptosis. Myeloid-specific IL-4R α gene 20 deletion in established HF (initiated 4 w post-MI) in IL-4R $\alpha^{t/f}$ LvsM-Cre^{ERT2} mice significantly 21 reduced CD206⁺ macrophage proliferation and effectively depleted CD206⁺IL-4R α ⁺ cardiac 22 macrophages. This was associated with abrogation of LV remodeling progression, reduction of 23 cardiac fibrosis, and improved neovascularization. In vivo IL-4R α gene silencing in mice with 24 established HF effectively depleted cardiac CD206⁺IL-4R α^+ macrophages and reversed LV 25

remodeling, improving fibrosis, neovascularization, and dysfunction, and suppressed both local 26 and systemic inflammation. Lastly, alternatively activated CD206⁺ and CD163⁺ macrophages 27 were significantly expanded in human failing hearts and correlated with fibrosis. The majority of 28 CD163⁺ macrophages expressed IL-4R α and FIZZ3, the human homolog of FIZZ1. 29 **CONCLUSION:** Cardiac CD206⁺IL-4Ra⁺ macrophages proliferate and expand in HF and are 30 31 key mediators of pathological remodeling and fibrosis, in part through the secretion of FIZZ1. Inhibition of CD206⁺ macrophage IL-4R α signaling alleviates LV remodeling in ischemic 32 cardiomyopathy. 33

34

Key Words: CD206⁺ macrophages; fibrosis; heart failure; interleukin 4 receptor- α ; inflammation

36 CLINICAL PERSPECTIVE

37

38 <u>What is new</u>?

- In the failing heart after myocardial infarction (MI), CD206⁺ macrophages, primarily CCR2⁻,
 MHCII^{hi}, and LYVE1⁺, robustly proliferate with a subpopulation expressing IL-4Rα;
 myeloid-specific IL-4Rα deletion or IL-4Rα silencing *in vivo* tempered CD206⁺
 macrophage proliferation and alleviated LV dysfunction, fibrosis, and remodeling.
- M[IL-4] CD206⁺ bone-marrow derived macrophages induced upregulation of *Fizz1*, and
 FIZZ1-dependent cardiac mesenchymal myofibroblast differentiation; intramyocardial
 adoptive transfer of M[IL-4] macrophages induced cardiac remodeling and fibrosis.

Humans exhibit expansion of alternatively activated macrophages in the failing heart
 marked by CD206 and CD163 expression, with predominance of a subpopulation
 expressing IL-4Rα and Fizz3, the human homolog of *Fizz1*.

49 <u>What are the clinical implications</u>?

- An expanded pool of alternatively activated CD206⁺IL-4Rα⁺ cardiac macrophages are key
 drivers of LV remodeling in heart failure, inducing an immuno-fibrotic and para inflammatory response in part dependent on FIZZ1.
- Targeting IL-4 signaling in CD206⁺ macrophages represents a potential therapeutic approach to limit long-term cardiac remodeling in heart failure.

55 INTRODUCTION

Heart failure (HF) is characterized by local and systemic inflammation.¹ In ischemic 56 cardiomyopathy, activated macrophages expand in the failing myocardium and contribute to 57 tissue injury and adverse left ventricular (LV) remodeling.¹⁻⁵ Cardiac macrophages may be 58 59 classified as C-C motif chemokine receptor (CCR2)⁻ resident macrophages that are embryonically derived and maintained independent of blood monocytes, and CCR2⁺ 60 macrophages that are derived from monocyte recruitment.⁶⁻⁸ Acutely after myocardial infarction 61 (MI), resident CCR2⁻ macrophages are lost and replaced by Lv6C^{hi}CCR2⁺ monocytes and 62 inflammatory CCR2⁺ macrophages that later transition to reparative macrophages to facilitate 63 wound healing, accompanied by attendant proliferation of surviving resident macrophage 64 populations.^{3,6,9-11} Notably, in chronic ischemic cardiomyopathy, well after MI healing, the 65 expanded cardiac macrophage pool stems from both locally proliferating resident macrophages 66 and recruited CCR2⁺ monocytes,^{2,3,5,6,12} with overall predominance of locally sourced (CCR2⁻) 67 cells.^{3,5,12} CCR2⁺ macrophage abundance correlates with adverse LV remodeling in human 68 HF,² whereas inhibiting CCR2⁺ monocyte infiltration sub-acutely after MI improves LV 69 remodeling in mice,⁵ identifying CCR2 as a potential therapeutic target. In contrast, the roles of 70 71 locally sourced macrophage populations in the pathogenesis of LV remodeling in established HF are poorly defined. 72

Resident cardiac macrophages express several marker genes including Timd4, Lyve1, 73 and classical alternatively-activated (M2-like) macrophage markers Cd163 and Mrc1.^{2,6,13,14} In 74 the naïve mouse heart, CD206 (Mrc1)-expressing resident macrophages are primarily CCR2⁻ 75 and express high levels of the markers Ym1 and Fizz1.¹⁵ After acute MI, CD206⁺ macrophages 76 expand in the infarct and border zone (peaking at 7 d post-MI)^{15,16} to promote wound healing 77 and limit adverse remodeling.^{15,17} CD206⁺ macrophages are activated by Th2 cytokines IL-4/13, 78 and IL-10.¹⁸⁻²⁰ IL-4/13 are important inducers of a reparative and pro-fibrotic phenotype,^{18,19,21} 79 signaling through Type I or II IL-4 receptors containing the common alpha chain IL4R α , resulting 80

in STAT6-mediated activation of *Arg1*, *Mrc1*, *Fizz1* (*Retnla*), *Ym1*, and secretion of C-C motif
chemokine ligands (CCL)-17 and -22.^{18,20,22,23} In vivo administration of IL-4 acutely after MI
improves wound healing and remodeling via the modulation of CD206⁺ macrophages. However,
this beneficial effect is lost when IL-4 is given late after MI.^{15,24}

85 These prior studies highlight CD206⁺ macrophages as key mediators of the post-MI wound healing response. However, the importance of this macrophage population in the 86 chronically failing heart, which exhibits a considerably different immune cell profile,^{1,11} is 87 unknown. In chronic ischemic cardiomyopathy, locally sourced and proliferating cardiac 88 macrophages exhibit much greater Mrc1 and Fizz1 expression than monocyte-derived 89 macrophages.⁵ Moreover, in chronic pulmonary and renal disease, persistent M[IL-4/13] 90 activation or M2-like macrophage recruitment can contribute to tissue fibrosis.^{21,25} whereas we 91 have previously shown that the post-MI failing heart exhibits increased IL-4/13 expression 92 coincident with a Th2 CD4⁺ T-cell profile.²⁶ Hence, here we tested the hypothesis that 93 expansion of cardiac CD206⁺ macrophages, activated by IL-4 receptor signaling, are key 94 mediators of LV remodeling in chronic ischemic HF. 95

96 METHODS

97 Mouse models. All mouse studies complied with the National Research Council's Guide for the Care and Use of Laboratory Animals (revised 2011) and were locally approved by 98 Institutional Animal Care and Use Committees at the University of Alabama at Birmingham and 99 Washington University in St. Louis. CD45.2 (#000664) and CD45.1 (#002014) C57BL/6 mice, 100 Fizz 1^{-/-} mice (#029976), and LysM-Cre^{ERT2} mice (#031674) were purchased from Jackson 101 Laboratory. Floxed IL4R α (IL4R α ^{t/f}) mice²⁷ were originally obtained from Dr. Frank Brombacher 102 (University of Cape Town) and bred with LysM-Cre^{ERT2} mice to generate IL-4Ra^{t/f}LysM-Cre^{ERT2} 103 mice that allow for tamoxifen-inducible myeloid-specific deletion of IL-4Ra. To induce Cre-104 mediated recombination, mice were fed tamoxifen citrate chow (40 mg/kg/d; Inotiv TD.130860). 105

As 400mg/kg tamoxifen citrate is sufficient to induce recombination,²⁸ IL-4Ra^{f/f}LysM-Cre^{ERT2} mice were considered to reach stable myeloid-specific IL4Ra deletion after 2 w of feeding. Male mice were used for experiments unless otherwise indicated. Mice were housed in temperaturecontrolled cages under a 12-hour light-dark cycle and given free access to water and regular chow. A total of 248 male and 37 female mice at 8-10 weeks of age were used. After terminal experiments, mice were euthanized by isoflurane inhalation (2%).

Murine surgical procedures. Permanent coronary ligation to induce large MI and ischemic HF, and control sham surgery, were performed under general anesthesia with 1-1.5% inhaled isoflurane and mechanical ventilation as previously described.^{4,26,29-31} For macrophage adoptive transfer, cell suspensions (1x10⁶ polarized macrophages in 50 μ L sterile PBS) or sterile PBS control alone were injected intramyocardially into the free wall of left ventricle (10 μ L/site x 5 sites) in naïve C57BL/6 male recipient mice.

Echocardiography. M-mode and 2-dimensional echocardiography were performed 118 under 2% inhaled isoflurane anesthesia (with 98% O₂) and continuous ECG monitoring using a 119 VisualSonics Vevo 3100 High-Resolution System and 30 MHz MX400 transducer with a heated, 120 bench-mounted adjustable rail system.^{4,26,29,32,33} Imaging was performed in the parasternal long-121 axis and short-axis views. LV chamber volume in end-diastole (EDV) and end-systole (ESV) 122 were quantitated using the area-length method from long-axis images captured in ECG-gated 123 Kilohertz Visualization mode. Systolic function was indexed by LV ejection fraction (EF), 124 calculated as [(EDV-ESV)/EDV] * 100. Stroke volume was defined as EDV-ESV. LV mass (mg) 125 was calculated as 1.05*[(IVSWTd+EDD+PWTd)³-(EDD)³], where IVSWTd and PWTd are 126 interventricular septal and LV posterior wall thickness at end-diastole, and EDD is the LV end-127 diastolic diameter derived from M-mode tracings. 128

Gene expression analysis. Total RNA from LV remote zones (≈10 mg), macrophages
 and cMSCs was extracted using Trizol (Invitrogen, 15596026) and Qiagen RNAeasy Columns

(QIAGEN, 74204)³⁴ and reverse transcribed to cDNA using the High-Capacity cDNA Reverse
 Transcription Kit (Applied Biosystems, 43-688-14). cDNAs were subjected to qPCR using SYBR
 Green Master Mix (Applied Biosystems, A25742) and run on a ViiA 7 RT PCR System (Applied
 Biosystems).^{32,35-37} Forward and reverse primer sequences are listed in <u>Supplemental Table 1</u>.

Multiplex Luminex assay. Peripheral blood was coagulated on ice and centrifuged to separate serum. Cytokine Luminex assay of serum samples was performed in 96-well Bio-Plex Pro Mouse Cytokine microplates and analyzed using the Luminex reader (BIO-RAD, Bio-PlexTM 200 system) according to the manufacturer's protocol.³⁴ Bio-Plex Pro Mouse Cytokine 23-plex Assay (M60009RDPD), MIP-2 Set (171G6006M), TGF-β1 Set (171V4001M), Standards Group I (171I50001), Group II Standards (171I60001), TGF-β Standard (171X40001) and Reagent Kit V (12002798) were all purchased from BIO-RAD.

142Immunoblot analysis.Immunoblotting was conducted using standard protocols as143described previously, 33,34,36 using antibodies against mouse Notch1 (Cell Signaling, 4380), NICD144(Cell Signaling, 4147) and α-SMA (Abcam, ab7817).GAPDH (Cell Signaling, 97166) and α-145tubulin (Santa Cruz, 5286) were used as loading controls.

Immune cell isolation and flow cytometry. Live mononuclear cells were isolated from 146 and processed for flow cytometry as previously peripheral blood and heart tissue 147 described.^{26,29,38} After 1% paraformaldehyde fixation, isolated cells were resuspended in MACS 148 149 buffer (PBS with 2 mM EDTA and 0.5% BSA) and preincubated for 10 min at 4°C with antimouse CD16/CD32 antibody (eBioscience, #14-0161-82) to block Fcy receptors.³² Cells were 150 then stained for surface membrane markers upon incubation with fluorophore-labeled anti-151 mouse CD45, F4/80, MERTK, CD11b, Ly6G, Ly6C, CD3, CD4, CD8, IL-4Rα, IL-10Rα, MHCII, 152 LYVE1, and CCR2, and, for human cardiac mononuclear cells, anti-human CD45, CD64, 153 CD206 and CCR2 for 1 h. Mouse cardiac mononuclear cells were then permeabilized with 0.5% 154 Tween-20 for 20 minutes, followed by staining with anti-mouse CD206 and Ki67 for 1 h. All 155

staining was performed on ice to maintain cell morphology. Flow cytometry was performed
using a FACSdiva LSR-II flow cytometer (BD) and analyzed using FlowJo software v10.8.0.
Specific details regarding the fluorophore-conjugated antibodies used are listed in <u>Supplemental</u> *Table 2*.

160 (Immuno)histological analysis. Formalin-fixed, paraffin-embedded heart tissues were sectioned at 5 µm thickness, deparaffinized, and rehydrated. Cardiomyocyte cell membranes 161 and capillaries were stained using Alexa Fluor (AF)555-conjugated wheat-germ agglutinin 162 163 (Invitrogen, #W32464) and AF488-conjugated isolectin-IB₄ (Invitrogen, #121411). respectively.^{4,26,29,32}. After antigen retrieval, LV sections were stained with anti-mouse CD206 164 (1:50, R&D AF2535, secondary anti-goat AF555), Ki67 (1:50, eBioscience 14-5698-82, 165 166 secondary anti-rat AF488), CD45.2 (1:50, eBioscience 14-0454-82, secondary anti-mouse AF647), α-actinin (1:100, Sigma A2172, secondary anti-mouse AF555), IL-4Rα (1:50, Invitrogen 167 PA5-103142, secondary anti-rabbit AFF647) and FIZZ1 (1:50, R&D MAB-1523, secondary anti-168 rat AF488) or anti-human CD163 (1:100, Leica Biosystems CD163-L-CE, secondary anti-mouse 169 IgG1 AF647), IL-4Ra (1:50, R&D MAB230, secondary anti-mouse IgG2a AF488) and FIZZ3 170 (1:50, R&D AF1359, secondary anti-goat AF555) antibodies. After permeabilization with 20 171 μ g/ml proteinase K, α -actinin stained LV sections were incubated with TUNEL reaction mix 172 (Biotium 30063) for 2h at 37°C. CD206 or CD163 stained LV sections were incubated with 15 173 µM heat-dissociated collagen hybridizing peptide 5-FAM Conjugate (F-CHP) (3Hekix FLU300) 174 overnight at 4°C. In addition, LV frozen sections (8 μm) were fixed with acetone/chloroform, 175 rehydrated, and stained with anti-mouse F4/80 (1:100, Abcam ab6640, secondary anti-rat 176 177 AF488) and α -actinin (1:100, Sigma A2172, secondary anti-mouse AF555) antibodies. Nuclei were stained with DAPI. Images were acquired using a Nikon A1 confocal microscope. Fibrosis 178 was measured in LV sections using Masson's Trichrome staining, and images were captured by 179 180 a Nikon 80i Nomarski DIC microscope. Collagen (blue) staining percent of total cross-sectional

area was determined as previously described.^{4,26,29,32} Staining was quantified from more than 5
 high-power fields (40x) per section using Nikon NIS-Elements software, version 4.60.00.

Bone marrow macrophage culture and adoptive cell transfer. C57BL/6 (CD45.2) or 183 Fizz1^{-/-} mouse bone marrow (BM) cells were harvested aseptically and cultured in RPMI 1640 184 medium, supplemented with 10% fetal bovine serum (FBS), 1% penicillin-streptomycin (PS) and 185 30 ng/mL recombinant mouse macrophage-colony-stimulating factor (M-CSF, R&D, 416-ML) at 186 37°C. The supernatant was replaced with fresh complete medium containing 30 ng/mL M-CSF 187 every 3 days for the attached cells, following the protocol of Trouplin et al.³⁹ After 7 days of 188 differentiation, BM-derived macrophages (BMDMs) were cultured in RPMI 1640 with 10% FBS 189 and 1% PS for 24 h for M0 (resting) macrophages, with 40 ng/mL recombinant mouse IL-4 190 (R&D, 404-ML) for M[IL-4] macrophages, and with 40 ng/mL recombinant mouse IL-10 (R&D, 191 417-ML) for M[IL-10] macrophages. Polarized macrophages were then mechanically detached, 192 and cell aliguots were stained with anti-mouse CD45, F4/80 and CD206 (Supplemental Table 2) 193 and analyzed using a flow cytometer to evaluate macrophage purity. After 24 h of polarization, 194 M0, M[IL-4] and M[IL-10] cells were rinsed with PBS and cultured in FBS-free medium for 3 h. 195 The macrophage conditioned medium was subsequently collected for treatment of cardiac 196 197 mesenchymal stem cells and fibroblasts, as described below. The polarized macrophages were used for studies of intramyocardial adoptive cell transfer into naïve male CD45.1 C57BL/6 mice 198 as described above. 199

In vivo antisense oligonucleotide administration. Second-generation chimeric 20base IL-4Rα antisense oligonucleotides (ASOs) (CCGCTGTTCTCAGGTGACAT) and control mismatched oligonucleotides (MM oligos) (CCGCTCATCACTGCTGACAT) were synthesized by Integrated DNA Technologies (IDT). All 20-base oligonucleotides were designed to avoid murine immune-stimulatory motifs, and contained phosphorothioate backbones and 2'-Omethoxyethylribose (MOE)-modification on bases 1–5 and 16–20 as described previously.^{40,41} Oligonucleotides were suspended in sterile saline and administered every 3 days (40 mg/kg,

total volume 10 μ L saline/g body weight) by intraperitoneal injection.⁴¹ Male C57BL/6 shamoperated and HF mice (4 w post-MI) with comparable degrees of LV remodeling were randomized to receive either IL-4R α ASOs (Ref 219428745, IDT) or MM oligos (Ref 219428746, IDT) for 4 w.

In vivo phagocytosis assay. To assess cardiac macrophage phagocytosis *in vivo*, pHrodo[™] green-E. coli bioparticles (Invitrogen, P35366) were injected intraperitoneally to mice (200 µg/mouse) 4 h before sacrifice. After sacrifice, heart mononuclear cells were collected and cell surface marker staining performed with anti-mouse CD45, F4/80, MERTK and CD206 as described above. Bioparticle uptake in live macrophages was measured by flow cytometry.

Cardiac mesenchymal stem cell (cMSC) studies in vitro. Sca1⁺CD90⁺CD31⁻DDR2⁻ 216 cMSCs were isolated from mouse hearts and maintained in supplemented [DMEM]/Ham's F-12 217 culture medium as previously described,³³ and used within 3-5 cell passages for all experiments. 218 For isolated cell stimulation studies, cMSCs were treated at the indicated times with serum-free 219 conditioned RPMI 1640 medium from M0, M[IL-4], or M[IL-10] macrophages described above 220 (or control media alone), with some experiments performed in the presence of either 1.5 μ g/mL 221 222 Fizz1 neutralization antibody or IgG isotype control (antibodies-online.com, ABIN636644 and ABIN1881001, respectively). In separate studies, cMSCs were treated with recombinant mouse 223 Fizz1 (Leinco Technologies, R1140) at the indicated concentrations and times in serum-free 224 RPMI 1640 medium. 225

226 **Collagen gel-contraction assays**. These were performed as previously described.³³ 227 Briefly, cMSCs in ice-cold 10% FBS DMEM medium mixed with 1 mg/mL rat tail collagen I were 228 plated in 48-well tissue culture plates at a density of 3x10⁵ cells/well. The cell suspension was 229 incubated at 37°C for 30 minutes until gelation. After gel formation, an additional 0.5 mL of 10% 230 FBS DMEM medium was added to each well and incubated overnight at 37°C in a 5% CO₂ 231 incubator. The supernatant was then removed and the gels treated with 0.5 mL conditioned

RPMI 1640 medium from M0, M[IL-4], or M[IL-10] macrophages with 10% FBS (or media alone
control), with or without anti-Fizz1 or IgG isotype control (1.5 μg/mL), as described above. Some
experiments were performed upon incubation with IL-4 or IL-10 alone (40 ng/mL) in 10% FBS
RPMI 1640 medium. The cells were cultured and treated for 5 d with medium change every 2 d.
On day 5, the gels were detached from the wells using a pipette tip and incubated overnight. On
day 6, the gels were imaged with a digital camera and gel area was measured using Image J
software (1.51j8, NIH).

siRNA transfection of cMSCs. cMSCs were transfected with siRNA using INTERFERin
 Reagent (Polyplus, 101000028) according to the manufacturer's protocol. Control siRNA
 (4390843) and siRNA targeting Notch1 (4390771) were purchased from Invitrogen.

Cardiac fibroblast studies *in vitro*. Mouse cardiac fibroblasts were purchased from
 iXCells biotechnologies (10MU-015) and grown in fibroblast growth medium (MD-0011) at 37°C
 in a humidified 5% CO2 atmosphere. Cells were used within 1-3 passages and treated with M0,
 M[IL-4], or M[IL-10] conditioned medium for 24 h.

Human studies. Following patient consent, failing heart tissue was procured from 246 patients with advanced (NYHA IV) HF with reduced EF undergoing LV assist device (LVAD) 247 placement at the University of Alabama at Birmingham (UAB) under the auspices of Institutional 248 Review Board (IRB) approved protocol #X090810003. Non-failing control heart tissues were 249 250 obtained from donor hearts technically unsuitable for heart transplantation from the Alabama Organ Center. All protocols using human heart samples were approved by the UAB IRB. Failing 251 and control human heart tissues were used for cardiac immune cell isolation and subsequent 252 flow cytometry, as well for histological analysis. Clinical characteristics of human HF subjects 253 254 and donor controls are shown in Supplemental Table 3.

Statistical Analysis. All group data are mean \pm SD. All statistical analyses were performed with GraphPad Prism 9 (GraphPad Software). Normality was assessed using the Shapiro-Wilk test, whereas group variances were compared using the Brown-Forsythe test. For

normally distributed data, a two-tailed unpaired Student's *t* test with equal or unequal variance was used for two-group analyses, and 1- or 2-way ANOVA with Tukey's post-test was used for multi-group analyses. Additionally, 2-way repeated-measures ANOVA with Dunnett's multiple comparison test was used to analyze time series pre-post data. For non-normal distributions, the Mann-Whitney U test was used for 2-group analyses. Pearson R correlation test was used for linear dependence analyses. Specific approaches are in the figure legends. A *p* value of <0.05 was considered statistically significant.

265 **RESULTS**

Cardiac CD206⁺ macrophages progressively expand during the development of 266 chronic HF post-MI. Cardiac macrophage subsets were profiled using flow cytometry at 267 various timepoints following non-reperfused large MI during the development of ischemic 268 HF,^{4,26,29,36} and in sham-operated controls (*Figure 1A*). As shown in *Figures 1B-C and S1A*, 269 following MI there was significant cardiac accumulation of both overall CD45⁺ leukocytes and 270 total F4/80⁺MERTK⁺ macrophages in a biphasic manner, with high levels at 48 h after injury, 271 subsequent decline by 2 w, followed by a second phase of re-expansion up to 8 w post-MI 272 during chronic LV remodeling and failure. In the failing heart 8 w post-MI, macrophages 273 274 comprised nearly two-thirds (~63%, or ~140,000 cells per heart) of all cardiac leukocytes and were increased by ~9-fold over macrophage levels in sham-operated hearts. Similar dynamics 275 were observed for the blood levels of pro-inflammatory Ly6C^{high} monocytes, an important source 276 of infiltrating macrophages,^{3,5,10,32,42} during the progression of ischemic HF. No significant 277 differences were observed in the levels of patrolling Ly6C^{low} monocytes between sham-operated 278 and HF mice at any time point evaluated (Figures S2A-C). 279

We next further evaluated macrophage subsets in the mouse heart. Naïve murine hearts harbored low numbers of macrophages (~20,000/heart), of which ~90% expressed the resident macrophage marker CD206 (*Figure 1C*). However, acutely (48 h) after MI, CD206⁺ macrophages comprised only ~20% of overall macrophages in the heart, in the setting of a

marked expansion of CD206⁻ macrophages early after MI. Thereafter, both the frequency and 284 absolute number of CD206⁺ macrophages steadily increased in post-MI hearts during the 285 286 progression of LV remodeling, such that at 8 w post-MI ~85% of cardiac macrophages expressed CD206. In contrast, CD206⁻ macrophage levels decreased markedly by 2 w post-MI, 287 and then exhibited smaller sustained increases in chronically failing hearts thereafter. Both 288 populations were significantly increased as compared to sham-operated hearts at all timepoints 289 post-MI. Hence, macrophages expand significantly in the chronically remodeled and failing heart 290 post-MI, and most of these macrophages express CD206. 291

292 **Cardiac CD206⁺** macrophages robustly express IL-4R α in chronic HF. Two key activators of CD206⁺ macrophages are IL-4/13, acting via Type I or II IL-4 receptors (IL-4R) 293 containing the common subunit IL4R α ,⁴³⁻⁴⁵ and IL-10, signaling through the IL-10 receptor (IL-294 10R) complex upon binding to the high affinity IL-10R α (IL-R1) subunit.^{46,47} As illustrated in 295 Figure 1D, both CD206⁺IL4R α^+ and CD206⁺IL-10R α^+ macrophage subpopulations were 296 significantly increased in comparison to sham-operated hearts at all time points after MI. 297 However, there was substantial expansion of the CD206⁺IL4R α ⁺ population over time, such that 298 at 8 w post-MI, levels of CD206⁺IL-4R α ⁺ cells (~45,000 per heart) were ~8-fold higher than 299 CD206⁺IL-10R α ⁺ cells and comprised ~42% of all CD206⁺ macrophages in the chronically failing 300 heart. In contrast, at 1 w post-MI, during the healing phase, CD206⁺IL-10R α ⁺ macrophages 301 were more abundant than CD206⁺IL-4R α^+ cells, comprising ~40% of all CD206⁺ macrophages 302 in the heart. Notably, neither IL-4R α nor IL-10R α were abundantly expressed by cardiac 303 CD206⁻ macrophages (<3% of cells) at any timepoint post-MI, and CD206⁻ macrophages 304 expressing either IL-4R α or IL-10R α numbered fewer than 500 cells/heart in the chronic stages 305 of LV remodeling (*Figure S1B*). In addition, IL-4R α and IL-10R α expression was also very low in 306 blood neutrophils (<1.5%), Ly6C^{low} monocytes (<2%) and Ly6C^{high} monocytes (<5%) in both 307 sham and HF mice (Figure S2). 308

309 Regarding Th2 cytokines, serum levels of IL4 and IL-10 were significantly higher in MI 310 mice as compared with sham mice during both the healing phase (1 w) and chronic remodeling phase (8 w) post-MI, whereas levels of IL-13 and TGF-β1 were comparable in sham and MI 311 mice at all timepoints (Figure S3A). In contrast, serum levels of the pro-inflammatory cytokines 312 313 TNF- α , IFN- γ , IL-1 β , MCP-1 and MIP-2 α in HF mice were increased over sham controls during both the early and late phases of remodeling after MI (Figure S3B), consistent with ongoing 314 systemic inflammation in HF mice. Hence, CD206⁺ macrophages in the failing heart primarily 315 express IL-4R α (versus IL-10R α); this is accompanied by increased circulating levels of both IL-316 4 and IL-10. 317

CD206⁺ macrophages in the failing heart proliferate, are primarily CCR2⁻, MHCII^{hi}, 318 and LYVE1⁺ and correlate with LV dysfunction and fibrosis. At 8 w post-MI, HF mice 319 exhibited significant LV systolic dysfunction and fibrosis (Figure 2A and S4A). Cardiac CD206⁺ 320 macrophage abundance inversely correlated with LVEF (r = 0.695), and directly correlated with 321 border and remote zone fibrosis (r = 0.755 and 0.644, respectively). Tissue co-staining with anti-322 CD206 and fluorescein-conjugated collagen hybridizing peptide (CHP) that recognizes 323 324 denatured collagen⁴⁸ revealed that CD206⁺ macrophages were primarily found in areas of collagen turnover in the failing heart, with >98% of macrophages associated with CHP-positive 325 regions in the infarct and border zones, and >80% CHP-associated cells in the remote 326 myocardium (Figure 2B). To infer the source of CD206⁺ macrophage expansion in the failing 327 heart, we measured the expression of markers CCR2, MHCII, and LYVE1 by flow cytometry 328 (Figure 2C). In sham hearts, >90% CD206⁺ macrophages were CCR2⁻, and of these, ~95% 329 were LYVE-1⁺, indicating a primarily resident macrophage population. In failing hearts, the 330 proportion of CD206⁺CCR2⁻LYVE1⁺ macrophages decreased significantly but remained high at 331 ~80% of total CD206⁺ cells, suggesting resident cell predominance but with an increased 332

contribution from monocyte-derived macrophages. Moreover, in both sham and failing hearts,
 the majority (~70%) of CD206⁺ macrophages were MHCII^{hi}.

Resident macrophage expansion requires local cell proliferation. As shown in Figure 2D 335 and S4B, immunostaining for CD206 and the cell proliferation marker Ki67 revealed that both 336 337 total CD206⁺ and Ki67⁺CD206⁺ macrophages were robustly expanded in the failing heart (8 w post-MI) as compared to sham. Cell density was greatest in the infarct zone (855 cells/mm²; 9% 338 Ki67⁺), followed by the border zone (584 cells/mm²; ~8% Ki67⁺) and then the remote zone (290 339 cells/mm², Ki67 positivity ~3% similar to sham hearts). Complementary assessment using flow 340 cytometry demonstrated that in both sham and failing hearts only CD206⁺ macrophages 341 exhibited Ki67 positivity (Figure 2E). Moreover, as compared to sham, failing hearts evidenced 342 ~3-fold higher levels of CD206⁺Ki67⁺ macrophages (~10% total), confirming augmented local 343 proliferation of CD206⁺ macrophages. In parallel, myocardial gene expression of Th2 cytokines 344 IL-4 and IL-10 (but not IL-13) and classical alternatively-activated macrophage markers Mrc1 345 (CD206), Arg1, Ym1 and Fizz1 was significantly increased in failing versus sham hearts (Figure 346 <u>S4C</u>), Concomitantly, the expression of fibrotic genes (Col)1 α 1, Col1 α 2, and Col3 α 1 was 347 markedly increased in failing hearts. Collectively, these data support expansion of a Th2/M2-like 348 immuno-fibrotic response in the chronically failing heart post-MI. 349

IL-4 polarization *in vitro* induces a profibrotic phenotype in CD206⁺ macrophages. 350 351 Bone marrow-derived macrophages (BMDMs) were polarized with either IL-4 or IL-10 (40ng/mL), or medium alone (M0 control), for 24 h (*Figure 3A*). Flow cytometry indicated that 352 while BMDMs were primarily CD206⁺ under resting (M0) conditions, both IL-4 and II-10 353 exposure augmented BMDM CD206 expression to ~98-99% of total cells. As shown in Figure 354 <u>3B</u>, the expression of signature M2 genes^{15,18,20,49,50} Mrc1, Arg1, and Ym1 significantly increased 355 in both M[IL-4] and M[IL-10] macrophages (with much more Arg1 and Ym1 expression in M[IL-4] 356 cells) as compared to non-polarized M0 macrophages. In contrast, expression of Fizz1 (found in 357 inflammatory zone 1), a protein secreted during Th2 responses^{51,52} and implicated in 358

myofibroblast differentiation and lung fibrosis, ^{53,54} only increased in M[IL-4] macrophages, and to 359 extraordinary levels (>7,500-fold). Conversely, B7-H4 was exclusively, albeit modestly, 360 upregulated in M[IL-10] macrophages. Changes in macrophage gene expression were noted 361 after 4 h of polarization (Figure S5A) and were maintained or augmented after 48 h (Figure 362 363 S5B). A range of responses was observed for inflammatory and repair-associated genes in BMDMs after 24 h of polarization in vitro (Figure S6A). Surprisingly, there was no upregulation 364 of profibrotic genes TGF-β1 and platelet-derived growth factor (PDGF)-BB in M[IL-4] and M[IL10] 365 macrophages as compared to M0 cells, although there was augmented expression of tissue 366 inhibitor of matrix metalloproteinase (TIMP)-1 and TIMP-3 in both M[IL-4] and M[IL-10] 367 macrophages. 368

In parallel experiments, conditioned medium was collected from M0, M[IL-4] and M[IL-10] 369 macrophages and applied to Sca1⁺CD90⁺CD31⁻DDR2⁻ cardiac MSCs³³ (*Figure 3A*). cMSC 370 gene expression was then evaluated after 6 and 16 h of exposure. Short-term (6 h) exposure to 371 M[IL-4] medium induced significant upregulation of the proliferation genes PCNA, Mki67, 372 CyclinB1 and CyclinD1 as compared to M0-medium, and to a greater extent than upon 373 exposure to M[IL-10] medium. Longer-term (16 h) exposure induced similar expression 374 responses for cMSC pro-fibrotic genes, including α -smooth muscle actin (α -SMA), Col1 α 1. 375 $Col1\alpha 2$, and $Col3\alpha 1$ (Figure 3C). The functional impact of macrophage polarization on cMSCs 376 was assessed using collagen gel contraction assays³³ after 5 d of exposure to M0, M[IL-4], 377 M[IL-10] medium, or medium alone control. As illustrated in Figure 3D, M[IL-4] medium 378 exposure induced robust gel contraction, significantly greater than with exposure to either M0 or 379 380 M[IL-10] medium (or control), consistent with vigorous cMSC myofibroblast differentiation. Importantly, exposure to complete medium containing IL-4 or IL-10 alone (40 ng/mL) did not 381 induce cMSC gel contraction (Figure S6B), indicating an indispensable role for CD206⁺ 382 macrophages in IL-4-induced cMSC myofibroblast differentiation. Similarly, 24 h treatment with 383

M[1L-4] medium robustly increased α -SMA protein expression in mouse cardiac fibroblasts as compared with similar treatment with M0 or M[IL-10] medium (*Figure S6C*). Collectively, these data suggest that IL-4-mediated macrophage polarization supports pro-fibrotic responses in concert with striking upregulation of *Fizz1*.

Adoptive transfer of M[IL-4] macrophages to naïve hearts induces cardiac 388 dysfunction and fibrosis. To evaluate the in vivo cardiac effects of M[IL-4] and M[IL-10] 389 macrophages, we adoptively transferred 1x10⁶ M0, M[IL-4], or M[IL-10] bone marrow-derived 390 macrophages from CD45.2 male mice to naïve WT CD45.1 male mice (PBS control) via 391 intramyocardial injection, with subsequent follow-up over 4 w (Figure 4A). Immunostaining of 392 injection sites of recipient hearts 30 minutes post-injection confirmed successful transfer of M0, 393 394 M[IL-4], and M[IL-10] donor macrophages (Figure S7A). Serial echocardiography of recipient mice revealed progressive and significant LV chamber dilatation, with increased EDV and ESV. 395 and systolic dysfunction, with reduced LVEF, along with LV hypertrophy, evidenced by 396 increased LV mass, IVSWTd, and PWTd by echocardiography and increased normalized heart 397 weight, in M[IL-4] macrophage recipients, but not in PBS, or M0 or M[IL-10] macrophage 398 recipients (Figures 4B and S7B and D). Stroke volume was comparable over time in all four 399 groups (Figure S7C). Histological analysis showed significantly increased patchy interstitial 400 401 fibrosis in M[IL-4]-recipient hearts as compared with PBS, M0, and M[IL-10] recipient hearts (Figure 4C), along with augmented cardiomyocyte cross-sectional area and apoptosis (Figures 402 4D and S7E). Importantly, CD45.2 and CD206 co-staining of recipient hearts demonstrated 403 donor macrophage persistence in adoptive transfer recipients, but to a significantly greater level 404 in M[IL-4] recipient mice. M[IL-4] (but not M0 or M[IL-10]) macrophage transfer also induced 405 expansion of native resident CD206⁺ macrophages. Both CD45.2⁺ donor and CD45.2⁻ recipient 406 407 CD206⁺ macrophages expansion occurred primarily at sites of collagen turnover and fibrosis in recipient hearts, with stronger such association for donor macrophages (Figures 4E and S7F), 408

There was no evidence of pro-inflammatory Ly6C^{hi} monocytosis in any recipient mouse group (*Figure S7G*), suggesting the absence of systemic inflammation after transfer. Collectively, these data establish that M[IL-4] polarized macrophages are sufficient to induce chronic cardiac remodeling, hypertrophy, and fibrosis, and a microenvironment supporting CD206⁺ macrophage expansion.

Myeloid-specific IL-4R α deletion in HF suppresses cardiac CD206⁺ macrophage 414 expansion and improves LV remodeling. Among myeloid cells, IL-4Ra expressions occurred 415 primarily in macrophages, with low levels in monocytes and neutrophils (Figure S2), and among 416 macrophages, primarily in CD206⁺ macrophages (Figures 1D and S1B). Hence, to establish the 417 role of CD206⁺IL4R α^+ macrophages in HF, we used IL-4R $\alpha^{t/f}$ LysM-Cre^{ERT2} mice. Given the 418 importance of the IL-4 axis in wound healing after acute MI^{15,24} and our observations that 419 cardiac CD206⁺IL-4R α^+ macrophage expansion in ischemic HF occurs most prominently >4 w 420 post-MI, we induced myeloid IL-4Ra deletion during late remodeling. Male and female IL-4Ra^{t/f} 421 and IL-4Ra^{f/f}LvsM-Cre^{ERT2} HF mice with comparable LV remodeling at 4 w post-MI (or sham-422 operated controls) were randomized to receive tamoxifen diet for 6 weeks (Figure 5A). In male 423 mice, echocardiography revealed significant LV dilation and systolic dysfunction in both HF 424 groups 4 w post-MI as compared to sham (Figure 5B). In contrast, as compared with tamoxifen-425 fed IL-4Ra^{t/f} HF mice, tamoxifen treatment for 6 w in IL-4Ra^{t/f}LysM-Cre^{ERT2} HF mice resulted in 426 427 lower LVEDV and ESV, better LVEF and stroke volume (SV), and smaller heart size and normalized heart and lung weight (Figures 5B, S8A-B). Moreover, histological analysis revealed 428 less border and remote zone fibrosis, smaller cardiomyocyte area, and improved capillary 429 density in male IL-4R $\alpha^{t/t}$ LysM-Cre^{ERT2} HF mice versus IL-4R $\alpha^{t/t}$ HF mice (*Figures 5C, S8C*). 430 Myeloid IL-4Rα deletion in HF in male mice also decreased levels of total leukocytes, CD206⁺ 431 and CD206⁻ (and CD206⁻IL4R α^+) macrophages, CD206⁺IL4R α^+ and CD206⁺IL10R α^+ 432 macrophages, and proliferating Ki67⁺CD206⁺ macrophages in the heart, as well as Lv6C^{hi} and 433

434 Ly6C^{hi}IL-4R α^+ monocytes (but not Ly6C^{low} monocytes) in the blood, as compared to HF mice 435 without myeloid IL-4R α deletion (*Figures 5D-F, S8D-F*). There were no effects of myeloid IL-436 4R α deletion on any parameter in sham male mice.

Comparable tamoxifen-induced effects were observed in female IL-4Ra^{f/f}LysM-Cre^{ERT2} 437 versus IL-4R $\alpha^{t/t}$ HF mice with regard to improvements in LV remodeling and systolic function 438 (albeit with less pronounced differences in LVEDV) (*Figure S9A-B*), heart and lung gravimetry 439 and weight (Figure S9C-D), and reductions in cardiac leukocytes and total macrophages (Figure 440 S10A), CD206⁺ and CD206⁻ macrophages, CD206⁺IL4R α ⁺ and CD206⁺IL10R α ⁺ macrophages, 441 and CD206⁻IL4R α^+ macrophages (*Figures S10B-C*). As in males no effects of myeloid IL-4R α 442 deletion on any of these parameters were observed in sham-operated female mice. Collectively, 443 these results indicate that CD206⁺IL4Ra⁺ macrophages are a key expanded myeloid cell 444 population in the failing heart that is necessary for driving progressive inflammation and 445 pathological cardiac remodeling, fibrosis, and dysfunction. Moreover, IL-4R α expression marks 446 447 a macrophage subpopulation with high proliferative capacity in the failing heart.

IL-4R α silencing in vivo reverses LV remodeling, reduces cardiac fibrosis, and 448 improves neovascularization in HF. To explore whether the macrophage IL-4R α axis could 449 be exploited for the rapeutic benefit in HF, we selectively silenced IL-4R α expression in vivo 450 using optimized antisense oligonucleotides (ASOs) targeting IL-4R α mRNA.^{40,41} IL-4R α 451 signaling mainly occurs in hematopoietic and lymphoid cells.⁴⁵ In humans, there is very low IL-452 453 4R RNA expression in heart cardiomyocytes and fibroblasts, with much more pronounced expression in immune cells, and in endothelial and smooth muscle cells 454 (https://www.proteinatlas.org/ENSG00000077238-IL4R/single+cell+type/heart+muscle). 455 То assure targeting of cardiac macrophages with this systemic approach, we performed flow 456 cytometry to evaluate IL-4R α expression in cardiac leukocytes. As shown in *Figure S11*, in both 457 sham and failing hearts, ~92% of all IL-4R α^+ CD45⁺ leukocytes were macrophages 458

(F4/80⁺MERTK⁺), while ~98% of IL-4R α ⁺ macrophages in failing hearts were CD206⁺. Moreover, circulating monocytes and neutrophils exhibited low levels of IL-4R α expression (*Figure S2*). Hence, IL-4R α ASOs represent a feasible and directed approach for dual inhibition of IL-4 and IL-13 signaling⁴⁵ in cardiac CD206⁺IL-4R α ⁺ macrophages.

Male sham-operated and HF mice with comparable degrees of LV remodeling at 4 w post-463 MI were randomized to receive either IL-4R α ASOs or MM oligos (40 mg/kg every 3 days) for 4 464 weeks (Figure 6A). Body weight was comparable between the two sham groups and two HF 465 groups over the 4 w treatment period (Figure S12A). Serial echocardiography revealed 466 significant and expected LV dilation and systolic dysfunction in both HF groups as compared to 467 468 sham groups (Figures 6B and S12B). Sham-operated mice exhibited no changes in LVEDV, 469 LVESV, stroke volume (SV), and LVEF during treatment with either IL-4R α ASOs or MM oligos. 470 HF mice treated with MM oligos evidence progressive increases in LV chamber size, and 471 reductions in LVEF and SV, over 4 w. In contrast, HF-IL-4R α ASO mice, which exhibited LV remodeling similar to HF-MM oligo mice at 4 w post-MI. exhibited significant reductions in EDV 472 and ESV, and improvements in SV and EF, indicative of reverse remodeling. Lung and heart 473 gravimetric analysis at 8 w post MI revealed substantially attenuated pulmonary edema and 474 cardiac hypertrophy in HF-IL-4Ra ASO HF mice versus HF-MM oligo mice, without impact on 475 spleen weight (Figures 6C and S12C). 476

Histological evaluation with trichrome staining indicated significantly increased border and remote zone interstitial fibrosis in MM oligo-treated failing hearts as compared to MM oligotreated sham hearts (*Figure 6D*). Impressively, IL-4R α ASO treatment profoundly decreased both border and remote zone fibrosis in failing hearts. Fibrotic area in IL-4R α ASO-treated sham hearts was comparable to that of MM oligo-treated sham hearts. Isolectin B4 and wheat-germ agglutinin staining (*Figure 6E*) indicated that both HF-MM oligo mice and HF-IL-4R α ASO mice exhibited significantly increased myocyte cross-sectional area and lower myocardial

capillary:myocyte ratio versus their respective sham groups. Importantly, however, myocyte
 area was lower and capillary:myocyte ratio was higher in HF-IL-4Rα ASO mice versus HF-MM
 oligo mice, indicating alleviation of pathological hypertrophy and capillary rarefaction.

IL-4R α silencing in HF depletes cardiac CD206⁺IL-4R α ⁺ macrophages and 487 suppresses their proliferative and phagocytic capacity. As shown in Figures S13A and 6F, 488 4 w of IL-4R α ASO treatment significantly reduced the number of total CD45⁺ leukocytes (by 489 490 ~45%), total F4/80⁺MERTK⁺ macrophages (by~53%), and both CD206⁺ and CD206⁻ macrophages (by ~50%) in the failing heart. Moreover, IL-4R α ASO treatment specifically and 491 profoundly depleted CD206⁺IL-4Ra⁺ cardiac macrophages, while mildly augmenting CD206⁺IL-492 $10R\alpha^+$ macrophages in the failing heart (*Figure 6F*). IL-4R α ASO administration did not impact 493 leukocyte and total macrophage abundance in sham hearts. Notably, IL-4R α ASO therapy did 494 not impact in circulating IL-4 levels (nor IL-13 and TGF-β1 levels) in HF mice, whereas serum 495 IL-10 was significantly decreased (Figures 6G and S13B). Remarkably, total CD206-496 macrophages, including CD206⁻IL-4R α^+ and CD206⁻IL-10R α^+ macrophages, in failing hearts 497 498 were also diminished by IL-4R α ASO treatment (*Figure S13A*). Additionally, IL-4R α ASO treatment impacted CD206⁺ macrophage function in failing hearts, significantly reducing (by 499 ~50%) both CD206⁺ macrophage cell proliferation (Ki67 staining) and phagocytic capacity 500 (assessed in vivo using fluorescent bioparticles) in HF-IL-4Ra ASO mice as compared with HF-501 MM oligo mice (Figures 6H-I). The latter data are consistent with IL-4 serving as a potent 502 stimulator of macrophage proliferation.^{15,55} 503

⁵⁰⁴ IL-4R α ASO treatment in HF mice also abrogated systemic inflammation as evidenced ⁵⁰⁵ by normalization of circulating Ly6C^{hi} monocytosis (and levels of Ly6C^{hi}IL-4R α ⁺ monocytes) and ⁵⁰⁶ serum levels of pro-inflammatory protein mediators TNF- α , MCP-1, MIP-2 α and IL-1 β toward ⁵⁰⁷ those observed in sham mice (*Figure S13C-D*). Serum IFN- γ levels, however, were not ⁵⁰⁸ impacted by IL-4R α ASO treatment and remained high in HF-IL-4R α ASO mice as compared to

sham. Importantly, IL-4Ra ASO treatment in HF mice also alleviated T-cell expansion in both 509 the circulation and failing heart, with significant reductions in peripheral blood and cardiac CD4⁺ 510 and CD8⁺ T cells in in HF-IL-4Ra ASO mice as compared with HF-MM oligo mice (*Figure S14*). 511 Additionally, IL-4R α expression was very low (~1-2%) in blood and heart CD4⁺ and CD8⁺ T cells 512 in both sham and HF mice treated with MM oligo or IL-4R α ASOs. Taken together, these data 513 indicate that in vivo IL-4R α mRNA silencing was highly effective in improving pathological 514 cardiac remodeling, hypertrophy, fibrosis, and dysfunction, and in suppressing local and 515 systemic inflammation in chronic ischemic HF. 516

Fizz1 is essential for CD206⁺ macrophage-induced myofibroblast activation. FIZZ1, 517 also known as resistin-like molecule a (Retnla), is a 9.4 kDa cysteine-rich secreted protein 518 produced mostly by macrophages during Th2 responses.⁵⁰⁻⁵² As described above, macrophage 519 520 Fizz1 expression exponentially increased exclusively after M[IL-4] polarization (>7,500-fold after 24 h and >100.000-fold after 48 h) polarization and not with M[IL-10] polarization (Figures 3B 521 and S5B), and coincided with M[IL-4] macrophage-induced myofibroblast differentiation of 522 cMSCs (Figure 3C). Accordingly, we further evaluated the role of Fizz1 in pro-fibrotic cellular 523 responses. Exposure of cultured cMSCs to recombinant mouse (rm) Fizz1 induced, in a dose-524 525 dependent manner, the expression of proliferative genes PCNA, Mki67, CyclinB1 and CyclinD1 early (2 h), and profibrotic genes α -SMA, Col1 α 1, Col1 α 2, and Col3 α 1 late (16 h), after 526 treatment (Figure S15), analogous to changes observed with M[IL-4] medium treatment (Figure 527 3C). To determine the need for FIZZ1 in M[IL-4]-induced cMSC responses, we used anti-Fizz1 528 antibody to neutralize endogenous Fizz1 in M[IL-4] conditioned medium. As shown in Figure 529 <u>S16</u>, compared to IgG control, anti-Fizz1 significantly reduced the expression of mitotic genes, 530 α -SMA (by 40%) and Col3 α 1 in M[IL-4] conditioned media-treated cMSCs. Furthermore, anti-531 Fizz1 abrogated collagen gel contraction induced by M[IL-4] conditioned media (Figure 7A), a 532

phenomenon recapitulated by the use of Fizz1^{-/-} BMDMs (*Figure 7B*), indicating that secreted
 Fizz1 is essential for M[IL-4]-induced cMSC myofibroblast differentiation and activation.

Notch signaling is critical for cell proliferation, differentiation, and development, and 535 homeostasis;⁵⁶ Notch ligand binding to Notch receptors leads to release of Notch intracellular 536 domain (NICD) and subsequent transcription of target genes, including α -SMA, Cyclin D1, 537 *Cyclin A* and NF- κ B.⁵⁶ As α -SMA expression is critical for myofibroblast fate of mesenchymal 538 stromal cells,^{33,57}, we assessed the importance of Notch signaling in Fizz1-mediated α -SMA 539 expression in cMSCs. Fizz1 exposure significantly upregulated cMSC gene expression of the 540 Notch1 ligands DLL-4 and Jagged1 within 30 minutes (*Figure 7C*), followed by increased protein 541 542 expression of Notch1, NICD and α -SMA within 24 h (*Figure 7D*). Importantly, Notch1 siRNA knockdown prevented α -SMA (and NICD) upregulation in Fizz1-treated cMSCs, suggesting a 543 critical role for DLL-4/Jagged-Notch1 signaling in the pro-fibrotic effects of M[IL-4] macrophage-544 secreted FIZZ1. 545

In view of the importance of FIZZ1 in M[IL-4]-induced myofibroblast differentiation, we 546 next examined Fizz1 expression and spatial distribution using immunostaining in failing hearts 547 from MM oligo- and IL-4R α ASO-treated mice (8 w post-MI). Consistent with flow data, a robust 548 549 (~11-fold) expansion of CD206⁺ macrophages (both IL-4R α^+ and IL-4R α^-) was observed in MM oligo-treated failing hearts versus sham hearts, especially in the border zone (Figure 7E). IL-550 4Rα staining was observed near exclusively in CD206⁺ cells (*Figure S17*), further supporting 551 CD206⁺ macrophage-specificity of IL-4R α silencing, and Fizz1⁺ staining was near exclusively 552 spatially localized to IL-4R α^+ cells (~98% Fizz1⁺) in all groups (*Figure S17*). IL-4R α^+ Fizz1⁺ cells 553 comprised ~50% cardiac CD206⁺ macrophages in HF-MM oligo mice (*Figure 7E*). IL-4Ra ASO 554 treatment significantly decreased IL-4R α ⁺Fizz1⁺ (and IL-4R α ⁻Fizz1⁻) CD206⁺ macrophages in 555 556 failing hearts, and also diminished IL-4R α expression (assessed by fluorescence intensity) (Figure 7E). (Figures 7E and Figure S17). Hence, IL-4R α silencing in HF reduced CD206⁺ 557

macrophage FIZZ1 expression in the failing heart concomitantly with improvements in cardiac fibrosis. Taken together with the *in vitro* studies above, our results suggest that *Fizz1* may be a key contributor to the tissue level pro-fibrotic effects of CD206⁺IL-4R α^+ macrophages in the failing heart.

IL-4Ra⁺Fizz3⁺ alternatively activated macrophages expand and directly correlate 562 with fibrosis in human failing hearts. To understand translational relevance, we lastly 563 explored whether alternatively activated resident macrophages are expanded in human HF. As 564 565 mentioned above, resident cardiac macrophages express classical M2-like markers Mrc1 (CD206) and CD163.^{2,6,13,14} Cardiac mononuclear cells were isolated from the LV apex procured 566 from advanced HF patients during LVAD implantation, and from control donor hearts unsuitable 567 for transplantation. Analogous to murine HF, flow cytometry indicated significant expansion 568 (~10-fold) of CD206⁺ macrophages (CD45⁺Autofluorescence⁺CD64⁺) in human failing hearts 569 versus control, with ~20% of CD206⁺ macrophages expressing CCR2 (Figure 8A). Human 570 failing hearts also exhibited substantial (>200-fold) interstitial fibrosis versus control hearts, with 571 most (~95%) CD163⁺ macrophages found in association with areas of collagen turnover (Figure 572 8B), analogous to murine failing hearts. Fizz3 (resistin, Retn), the human homolog of murine 573 Fizz1, is expressed by M[IL-4/13] human macrophages and resembles mouse FIZZ1 with 574 respect to sequence and function.^{58,59} Accordingly, we performed immunostaining for IL-4R α , 575 Fizz3 and CD163, a widely used marker for alternatively-activated human macrophages.⁶⁰ As 576 shown in Figure 8C, human failing hearts exhibited significant expansion (~6-fold) of CD163⁺ 577 578 macrophages (both IL-4R α^+ and IL-4R α^-) as compared to control hearts. Fizz3⁺ staining was near exclusively spatially localized to IL-4R α^+ cells (~98% Fizz3⁺) in both human control and 579 580 failing hearts, similar to the IL-4R α and Fizz1 expression pattern observed in mouse hearts (Figure S17). Importantly, IL-4Ra⁺Fizz3⁺ cells comprised the predominant CD163⁺ macrophage 581 subset in human failing hearts, with approximately two-thirds of CD163⁺ macrophages 582

expressing IL-4R α and Fizz3⁺ (*Figure 8C*). CD163⁺ macrophage abundance directly correlated with cardiac fibrosis in human HF. Hence, analogous to murine HF, human failing hearts also evidence expansion of alternatively activated macrophages, likely with augmented IL-4 signaling and contributing to pro-fibrotic responses.

587 DISCUSSION

We describe a novel role for cardiac CD206⁺ macrophages alternatively activated by IL-588 4 receptor signaling in the progression of LV remodeling in ischemic cardiomyopathy. There are 589 several key findings. First, macrophages expressing CD206 comprised most macrophages in 590 the naïve heart. Following MI, cardiac CD206⁺ macrophages progressively expanded, especially 591 during the later stages of LV remodeling such that they comprised the predominant macrophage 592 population in chronic HF. Second, CD206⁺ macrophages were exclusively proliferative and 593 primarily CCR2⁻, MHCII^{hi}, and LYVE1⁺ suggesting a resident cell population, and correlated with 594 LV dysfunction and fibrosis. Second, a sizable subpopulation of these macrophages in HF 595 expressed IL-4R α ; this occurred with attendant increased systemic levels of IL-4. Third, M[IL-4] 596 (but not M[IL-10]) CD206⁺ BMDMs induced remarkable upregulation of *Fizz1*, and robust cMSC 597 myofibroblast differentiation. M[IL-4] CD206⁺ macrophage-induced myofibroblast differentiation 598 and activation were dependent on FIZZ1 secretion and mediated in part by FIZZ1 induction of 599 DLL-4/Jagged1-Notch1 signaling in cMSCs. Fourth, intramyocardial adoptive transfer of M[IL-4] 600 macrophages was sufficient to induce pathological cardiac remodeling and fibrosis. Fifth, 601 myeloid-specific IL-4Ra deletion tempered cardiac CD206⁺ macrophage proliferation and 602 alleviated LV dysfunction, fibrosis, and adverse remodeling. Sixth, IL-4R α silencing in vivo was 603 highly effective in depleting CD206⁺IL-4R α^+ macrophages, reducing FIZZ1 expression in the 604 failing heart, and reversing LV remodeling in mice with established HF. Lastly, humans exhibit 605 expansion of alternatively activated macrophages in the failing heart marked by CD206 and 606 CD163 expression, with predominance of a subpopulation expressing IL-4R α and Fizz3, the 607

human homolog of *Fizz1*. Collectively, these data establish that an expanded pool of alternatively activated CD206⁺IL-4R α^+ cardiac macrophages are key drivers of LV remodeling in HF, inducing a Th2/M2-like immuno-fibrotic response in part dependent on FIZZ1. Targeting IL-4 signaling in CD206⁺ macrophages may represent a fruitful therapeutic approach to limit longterm cardiac remodeling in HF.

Mrc1 (Cd206) and Cd163 are typically expressed by resident cardiac macrophages 613 under steady state conditions.^{2,6,13,14} Moreover, in the naïve heart, CD206⁺ macrophages 614 express high levels of classical M2-like genes such as Ym1 and Fizz1 and are primarily CCR2⁻ 615 ¹⁵ suggesting a macrophage subset with minimal monocyte-dependence.⁶ Prior work has 616 shown that CD206⁺ macrophages expand during the first week after acute MI in the infarct and 617 border zone to promote infarct repair and functional restoration.¹⁵⁻¹⁷ Administration of IL-4 618 acutely (but not late) after MI also expands CD206⁺ macrophages in the infarcted heart and 619 recapitulates beneficial effects on post-MI cardiac healing.^{15,24} However, the role of this 620 macrophage population, and the impact of macrophage IL-4 signaling, in chronic LV remodeling 621 and ischemic HF has not been defined. The chronically failing heart is typically marked by 622 excessive tissue fibrosis.⁶¹ Notably, in chronic pulmonary,^{62,63} hepatic,⁴¹ and renal²⁵ disease 623 models marked by excessive fibrosis, alternatively activated (CD206⁺ or CD163⁺) macrophage 624 activation mediated by Th2 cytokines such as IL-4 contribute to disease progression. While we 625 have previously shown that the post-MI failing heart exhibits increased IL-4 expression and a 626 predominant Th2 CD4⁺ T-cell profile,²⁶ whether a similar pathophysiological axis contributes to 627 LV remodeling in ischemic cardiomyopathy is unknown. 628

Our studies show that CD206⁺ macrophages progressively expand after MI, with particularly robust levels during the later stages of LV remodeling. Beyond the initial infiltration of predominantly (>80%) CD206⁻ macrophages into the heart early (48 h) after MI, CD206⁺ macrophages were the main subtype in the remodeling heart at 1 w post-MI and beyond,

633 comprising ~85% of all macrophages in HF. Moreover, in the failing heart 8 w post-MI, nearly half of all cardiac CD206⁺ macrophages expressed IL-4Ra. Notably, cardiac macrophage 634 proliferation was observed exclusively in CD206⁺ subpopulation in the failing heart. Although 635 spatially expanded throughout the myocardium, CD206⁺ macrophages were most abundant in 636 the infarct scar and border zone, and primarily in regions of collagen turnover and fibrosis. 637 Heightened macrophage proliferation was also mainly seen in the scar and border zones. This 638 suggests that progressive CD206⁺ macrophage expansion in these regions may contribute to 639 extracellular matrix remodeling, infarct expansion and LV chamber dilatation over time. Human 640 HF also evidenced marked expansion of alternatively activated (CD206⁺ or CD163⁺) cardiac 641 macrophages (consistent with a prior study of macrophages isolated from human failing hearts⁶⁴) 642 643 in association with regions of collagen denaturation and turnover, with a predominance of cells expressing IL-4R α analogous to murine HF. In this regard, IL-4 is a known stimulator of tissue 644 macrophage proliferation and resident macrophage self-renewal^{55,65} that also augments 645 macrophage CD206 expression⁶⁶ and promotes M2-like cardiac macrophage differentiation.¹⁵ 646 Consistent with our prior studies,²⁶ IL-4 levels were increased both locally in the heart and 647 systemically, suggesting that heightened IL-4 signaling may contribute importantly to sustaining 648 local inflammation and macrophage expansion in failing myocardium. 649

In both murine and human HF, the expanded cardiac CD206⁺ macrophage population 650 was primarily CCR2⁻ (~80%), MHCII^{hi}, and LYVE1⁺. In naïve¹⁵ and in sham-operated hearts, 651 CD206⁺ macrophages were also primarily CCR2⁻, albeit to much greater degrees (~95%) than 652 in failing hearts. As LYVE1 is considered a marker of resident macrophages,⁶ this suggests a 653 predominantly resident macrophage population that is expanded in failing hearts, but also with a 654 dual (albeit lesser) contribution from CCR2⁺ monocyte-derived cells. Prior work has shown that 655 after MI the absence of CCR2 expression does not exclude a monocyte origin as recruited 656 macrophages over time may exhibit transcriptional identities nearly identical to resident 657

macrophages.⁶ Our study design did not incorporate macrophage lineage tracing to definitively 658 address this question. Nonetheless, our data are consistent with prior work indicating that 659 cardiac macrophages derive from both local macrophage proliferation and recruited monocytes 660 (locally-sourced cells comprising ~75%) in chronic ischemic HF.^{3,5} Given our observations that 661 662 the proportion of CCR2⁺ cells increased significantly in failing hearts, and that cardiac macrophage abundance in post-MI HF was paralleled by similar dynamic changes in Ly6C^{high} 663 blood monocytes that source infiltrating macrophages,^{3,5,6,10} we propose that the expanded and 664 proliferative cardiac CD206⁺macrophage population derives from both resident and recruited 665 666 cells.

667 We evaluated the pathophysiological importance of CD206⁺IL-4R α ⁺ expansion in the failing heart by experimentally manipulating IL-4Ra signaling, which occurs largely in immune 668 cells.⁴⁵ While both M[IL-4] and M[IL-10] macrophage polarization induced the upregulation of 669 signature alternative macrophage activation genes, M[IL-4] polarization exclusively resulted in 670 extraordinary upregulation of Fizz1, and functional myofibroblast differentiation of cMSCs, 671 together with enhanced cMSC proliferative gene expression. Importantly, intramyocardial 672 673 adoptive transfer of M[IL-4], but not M[IL-10], macrophages produced significant long-term LV chamber dilatation, dysfunction, and fibrosis in naïve recipients. Hence, IL-4-mediated activation 674 of macrophages was sufficient to recapitulate chronic cardiac remodeling. 675

To establish the necessity of CD206⁺IL-4R α^+ macrophages in the pathogenesis of chronic LV remodeling, we evaluated the effects of myeloid IL-4R α deletion during established HF on subsequent LV remodeling. This manipulation primarily impacted macrophages in HF, given the very low levels of IL-4R α in neutrophils and monocytes. Notably, loss of macrophage IL-4 signaling via IL-4R α suppressed CD206⁺ macrophage proliferation, abrogated the progression of LV remodeling, improved LV systolic function and fibrosis, while suppressing both CD206⁺ and CD206⁻ macrophages in the heart as well as systemic Ly6C^{hi} monocytosis in

the blood. Beneficial effects of macrophage IL-4R α deletion were observed in both male and female mice. Hence, CD206⁺IL4R α ⁺ macrophages are indispensable for sustaining a chronic para-inflammatory response in failing myocardium that drives progressive cardiac remodeling in HF.

To explore a potential therapeutic avenue, we performed in vivo gene silencing of IL-687 $4R\alpha$ using ASOs, an approach that primarily targeted cardiac CD206⁺ macrophages given the 688 689 aforementioned low distribution of IL-4Ra expression observed in other myeloid and lymphoid cell populations in chronic HF. IL-4R α silencing in chronic ischemic HF very effectively depleted 690 cardiac CD206⁺IL-4R α^+ macrophages and suppressed their proliferation and phagocytic 691 capacity, while inducing impressive reverse LV remodeling with improvements in cardiac fibrosis, 692 693 neovascularization, and function, and suppression of both local and systemic inflammation (e.g., blood and cardiac CD4⁺ and CD8⁺ T cell levels). Taken together, our results underscore the 694 695 pathological effects of chronic macrophage IL-4R α activation in the failing heart and establish CD206⁺IL-4R α^+ macrophages as key mediators of pathological remodeling of the failing heart. 696 Our data support biological or pharmacological blockade of the IL-4/IL-4Ra pathway as a novel 697 698 immunomodulatory paradigm in HF. For instance, antagonistic antibodies against IL-4R α are currently being developed for allergic disorders in humans,⁶⁷ and could potentially be 699 repurposed for HF. 700

CD206⁺ macrophage abundance in murine failing hearts (or CD163⁺ macrophage abundance in human HF) correlated with the extent of cardiac fibrosis in chronic HF, and a prominent feature of IL-4-mediated CD206⁺ macrophage activation *in vitro* and *in vivo* was the induction of pro-fibrotic responses. Our data suggest that the protein FIZZ1 secreted by M[IL-4] macrophages may play an important role in this crosstalk, given: 1) *in vitro* studies demonstrating incredibly robust macrophage *Fizz1* upregulation upon IL-4 stimulation, 2) FIZZ1 dependence of the induction of cMSC myofibroblast differentiation by M[IL-4] macrophages,

potentially via DLL-4/Jagged1-Notch1 signaling, 3) exclusive expression of Fizz1 by cardiac 708 709 CD206⁺IL-4R α ⁺ macrophages in chronic HF, and 4) exclusive expression of FIZZ3 (resistin), the human homolog of FIZZ1,⁵⁸ by CD163⁺IL-4Rα⁺ macrophages in human failing hearts. FIZZ1 710 is secreted during Th2-type immune responses in mice.^{52,68} and induces myofibroblast 711 differentiation and fibrosis in the lung,^{53,54} whereas FIZZ3 induces LV fibrosis and dysfunction 712 when overexpressed in rat heart⁶⁹ and is a serum risk prediction biomarker in HF patients.⁷⁰ Our 713 data are consistent with a key pro-fibrotic function for FIZZ1 in the failing heart, secreted by 714 alternatively-activated CD206⁺IL-4R α^+ macrophages as part of an overall Th2/M2-like 715 inflammatory milieu in the failing heart.²⁶ The elucidation of the precise role of Fizz1/Fizz3, and 716 717 the potential for therapeutic Fizz1/Fizz3 blockade in HF, will require further study.

In summary, we have established a novel immunoinflammatory framework in the failing heart with an expanded pool of alternatively activated CD206⁺IL-4R α^+ macrophages as key drivers of LV remodeling. These alternatively-activated macrophages induce a parainflammatory, immuno-fibrotic response, in part dependent on FIZZ1 expression, that promotes cardiac fibrosis and dysfunction. Our findings identify IL-4 signaling in CD206⁺ macrophages, and potentially FIZZ1/FIZZ3 elaboration, as novel and appealing therapeutic targets for immunomodulation to limit long-term cardiac remodeling in ischemic cardiomyopathy and HF.

725

726 ACKNOWLEDGEMENTS AND FUNDING

This work was supported by National Institutes of Health R01 HL157999 and HL147549 grants to SDP, and R01 HL137046 to TH.

729

730 **COMPETING INTERESTS**

There are no relevant author financial interests.

732

733 FIGURE LEGENDS

Figure 1. Cardiac CD206⁺ macrophages robustly expand and express IL-4R α in 734 heart failure (HF). A, Protocol for cardiac macrophage profiling by FACS in C57BL/6 mice at 735 the indicated time points after non-reperfused myocardial infarction (MI) or sham operation. B 736 737 and C, representative flow cytometry scatter plots (B) and group quantitation for cardiac macrophages (F4/80⁺MerTK⁺), and CD206⁺ and CD206⁻ subpopulations (C) from sham and MI 738 mice at the indicated times post-operation. Quantitation from naïve mice also shown. D, 739 Representative flow plots and group data for IL-4R α and IL-10R α expression in cardiac CD206⁺ 740 macrophages from the same mouse groups. Statistics: unpaired Student's t test; **p<0.01 vs 741 respective sham group in **C-D**; p<0.01 vs Sham-CD206⁻ in **C**. p<0.01 vs Sham-IL-10R α^+ in 742 **D**. N=6-8 per group. 743

Figure 2. Cardiac CD206⁺ macrophages are proliferative, primarily MHCII^{hi} and 744 LYVE1⁺, and correlate with LV dysfunction and fibrosis in heart failure (HF). A, 745 Representative long-axis 2-dimensional echocardiograms at end-diastole and heart trichrome 746 stains from HF mice 8 w after non-reperfused myocardial infarction (MI) and sham controls, 747 along with correlations between cardiac CD206⁺ macrophage number and LV ejection fraction 748 (LVEF), and border and remote zone (BZ and RZ) fibrosis in failing hearts. **B**, Representative 749 750 low and high magnification confocal images of failing heart (8 w post-MI) infarct, border, and remote zones (immuno)stained for CD206 (red) and collagen hybridizing peptide (CHP) (green), 751 with quantitation of CHP-associated and -unassociated CD206⁺ macrophages. DAPI (blue) was 752 used to label nuclei. Scale bar 50 µm. C, Flow plots and quantitation of CCR2 and LYVE1 753 expression in CD206⁺ macrophages and LYVE-1 expression in CD206⁺CCR2⁻ macrophages in 754 sham and HF hearts 8 w post-surgery, **D**, Low and high magnification confocal images of 755 CD206 (red) and Ki67 (green) immunostains of sham, and the infarct, border and remote zones 756 of failing hearts 8 w post-surgery, and quantitation of CD206⁺ macrophages and Ki67 757

expression frequency. Nuclei labeled by DAPI (blue); yellow arrows indicate CD206⁺Ki67⁺ cells. Scale bar 50 μ m. *E*, Flow plots and quantitation of Ki67 expression in both CD206⁺ and CD206⁻ cardiac macrophages from the same groups. Statistics: Pearson R correlation test in *Aa*; unpaired Student's t test in *C-E*. N=4-13 per group as indicated.

Figure 3. IL-4-polarized bone marrow derived macrophages (BMDMs) induce 762 cardiac mesenchymal stem cell (cMSC) myofibroblast differentiation in vitro. A, Protocol 763 for BMDM polarization and cMSC treatment with macrophage conditioned medium, and 764 representative flow plots of F4/80 and CD206 expression in polarized BMDMs. B, Expression of 765 the indicated genes in M0, M[IL-4], and M[IL-10] macrophages 24 h after polarization. C. 766 Expression of the indicated genes in cMSCs treated with M0, M[IL-4], and M[IL-10] conditioned 767 768 media for the indicated times, and representative cMSC-imbued collagen gel contraction assays upon exposure to M0, M[IL-4], and M[IL-10] conditioned media, or media alone (Ctrl), and 769 quantitation of gel areas. Statistics: 1-way ANOVA with post-hoc Tukey's multiple comparison 770 test; * p<0.05, ** p<0.01 vs. M0. N=5-6/group. 771

Figure 4. Adoptive transfer of M[IL-4] macrophages to naïve hearts induces 772 cardiac dysfunction and fibrosis. A, Protocol for intramyocardial adoptive transfer of M0, 773 M[IL-4], and M[IL-10] bone marrow derived macrophages (BMDMs) or PBS vehicle to naïve 774 775 mice. B, M-mode echocardiograms of M0, M[IL-4], and M[IL-10] BMDM recipient mice 4 w posttransfer (PBS control), along with group data for LV end-systolic and end-diastolic volume (ESV 776 and EDV), ejection fraction (EF) at indicated times post-transfer, and for echocardiographic LV 777 mass normalized to tibia length (TL), and end-diastolic interventricular septal and posterior wall 778 thickness (IVSWT and PWT) at 4 w post-transfer. C, Representative trichrome stains of 779 780 recipient hearts at 4 w post-transfer and corresponding quantitation of cardiac fibrosis. **D**, Top, cardiac wheat-germ agglutinin (WGA, red) staining and guantitation of myocyte cross-sectional 781 area; Middle, low and high magnification images of TUNEL (green) stained nuclei in 782 783 cardiomyocytes (α -Actinin, Red) and quantitation of apoptotic myocyte nuclei; and *Bottom*, Low

784 and high magnification confocal images of CD206 (red) and CD45.2 (gray) immunostains and quantitation of CD206⁺CD45.2⁺ and CD206⁺CD45.2⁻ macrophages in recipient hearts, all at 4 w 785 786 post-transfer. Green arrows indicate apoptotic myocyte nuclei, red arrows indicate CD206⁺CD45.2⁻ cells, and white arrows indicate CD206⁺CD45.2⁺ cells. DAPI (blue) was used to 787 label nuclei, E. Low and high magnification confocal images of CD206 (red) and CD45.2 (grav) 788 immunostaining and CHP staining (green), and quantitation of CHP-associated and -789 unassociated, CD45.2⁺ and CD45.2⁻ CD206⁺ macrophage ratios in M[IL-4] recipient hearts 4 w 790 post-transfer. Nuclei were labeled by DAPI (blue). Red arrows indicate CHP-unassociated 791 CD206⁺CD45.2⁻ cells and white arrows indicate CHP-unassociated CD206⁺CD45.2⁺ cells. 792 Statistics: repeated-measures 1-way ANOVA with post-hoc Dunnett's multiple comparison test 793 for time series within groups in **B**, 1-way ANOVA with post-hoc Tukey's multiple comparison test 794 between groups in **B-D**, and unpaired Student's t test in **E**; *p<0.05, **p<0.01 M[IL-4] vs. PBS; 795 [#]p<0.05, ^{##}p<0.01 M[IL-4] vs. M0; ^{\$}p<0.05, ^{\$\$}p<0.01 M[IL-4] vs. M[IL-10]; [△]p<0.05, ^{△△}p<0.01 vs. 796 BsIn. N=6-8 per group as indicated. 797

Figure 5. Myeloid-specific IL-4Rα deletion suppresses cardiac CD206⁺ 798 macrophages and alleviates LV remodeling in heart failure (HF). A, Protocol for myeloid-799 specific IL-4R α ablation in IL-4R $\alpha^{t/t}$ LysM-Cre^{ERT2} sham and HF mice (IL-4R $\alpha^{t/t}$ mouse control) 800 with tamoxifen administration in diet from 4 to 10 w post-MI or sham surgery. B. Representative 801 802 long-axis 2D echocardiograms at end-diastole from male sham and HF mice after 6 w of tamoxifen (10 w post-surgery), along with directional changes in LV end-diastolic and end-803 systolic volume (EDV and ESV) and LV ejection fraction (EF) over this time. C, Representative 804 trichrome stains of hearts from IL-4R $\alpha^{t/f}$ and IL-4R $\alpha^{t/f}$ LysM-Cre^{ERT2} sham and HF mice after 6 w 805 of tamoxifen (10 w post-surgery) along with fibrosis quantitation in the border and remote zone 806 (BZ and RZ). **D** and **E**, Representative flow plots for cardiac macrophages (F4/80⁺MerTK⁺), 807 CD206⁺ macrophages, and IL-4R α and IL-10R α expressing CD206⁺ subpopulations in IL-4R α ^{t/f} 808

and IL-4R $\alpha^{f/f}$ LysM-Cre^{ERT2} HF mice, along with quantitative group data from both sham and HF male mice after 6 w of tamoxifen. *F*, Representative flow plots and quantitation of Ki67 expression in cardiac CD206⁺ and CD206⁻ macrophages from IL-4R $\alpha^{f/f}$ and IL-4R $\alpha^{f/f}$ LysM-Cre^{ERT2} HF mice given tamoxifen for 6 w. Statistics: 2-way ANOVA with post-hoc Tukey's multiple comparisons between groups in *B-E*; unpaired Student's t test in in *F*. N=7-11 per group.

Figure 6. In vivo IL-4R α silencing depletes cardiac CD206⁺ macrophages and 815 reverses LV remodeling in heart failure (HF). A. Protocol for treatment with IL-4R α antisense 816 oligonucleotides (ASOs) or mismatched (MM) control oligonucleotides (oligo) in HF mice from 4 817 to 8 w after non-reperfused myocardial infarction (MI) (sham controls). B, Representative long-818 axis 2-dimensional echocardiograms at end-diastole from sham and HF mice treated with IL-819 4Ra ASOs or MM Oligos for 4 w (8 w post-surgery timepoint). Also shown are group data for LV 820 end-diastolic and end-systolic volume (EDV and ESV) and ejection fraction (EF) over the 821 treatment period. C, Gross images of hearts from IL-4Ra ASO- and MM Oligo-treated sham and 822 HF mice, and group data for lung and heart weight (LW and HW) normalized to tibia length (TL). 823 **D**, Representative trichrome stains of IL-4R α ASO- and MM Oligo-treated sham and failing 824 hearts, and fibrosis quantitation in the border and remote zone (BZ and RZ). E, Representative 825 cardiac isolectin B4 (IB4, green) and WGA (red) staining and quantitation of myocyte cross-826 sectional area and capillary:myocyte ratio in the LV RZ from IL-4Ra ASO- and MM Oligo-treated 827 828 sham and HF mice. F, Left, quantitation of cardiac CD206⁺ macrophages, and Middle and Right, flow plots and quantitation of IL-4R α and IL-10R α expressing subpopulations, in sham and HF 829 mice treated with IL-4R α ASOs or MM Oligos for 4 w. G. Serum levels of IL-4 and IL-10 from the 830 same groups. H and I, Representative flow cytometry histograms, dot plots, and quantitation of 831 cardiac Ki67⁺ (*H*) or bioparticle⁺ (*I*) CD206⁺ and CD206⁻ macrophages in IL-4R α ASO- and MM 832 Oligo- treated HF mice. Statistics: repeated-measures 1-way ANOVA with post-hoc Dunnett's 833

multiple comparison test for time series within groups in **B**; 2-way ANOVA with post-hoc Tukey's multiple comparisons between groups in **B-F**, **H**, **I**; unpaired Student's t test in **G**. **p<0.01 vs. respective Sham-MM Oligo; ^{##}p<0.01 vs. HF-MM Oligo at the same week post-surgery; $^{\Delta}p$ <0.05, $^{\Delta\Delta}p$ <0.01 vs. respective 4 w timepoint. N=5-8 per group.

Figure 7. Fizz1 is essential for CD206⁺ macrophage-induced myofibroblast 838 differentiation of cardiac mesenchymal stem cells (cMSCs). A, cMSC-imbued collagen gel 839 contraction assays upon exposure to M[IL-4] bone marrow-derived macrophage (BMDM) 840 841 conditioned media or media alone control (Ctrl) containing isotype IgG or anti-Fizz1 antibody with corresponding quantitation of gel areas. B, cMSC gel contraction assays upon exposure to 842 wild-type (WT) and Fizz1^{-/-} M0 or M[IL-4] BMDM conditioned media, and guantitation of gel 843 areas. N=3-5 per group for A-B. C, cMSC DLL-4 and Jagged1 gene expression after 30 844 minutes of treatment with either vehicle (Ctrl) or recombinant mouse (rm) Fizz1 50 ng/ml and 845 100 ng/ml. D, Immunoblotting and group quantitation for Notch1, Notch intracellular domain 846 (NICD), and α -smooth muscle actin (α -SMA) protein expression in cMSCs treated with either 847 vehicle Ctrl or rmFizz1 for 24 h following scrambled or Notch1 siRNA transfection. GAPDH 848 loading control. E, Representative low and high magnification confocal images of immunostains 849 for CD206 (red), IL-4Rα (white) and Fizz1 (green) of hearts from sham and HF hearts (border 850 zone) from MM Oligo- or IL-4R α ASO-treated mice, with quantitation of CD206⁺IL-4R α ⁺Fizz1⁺ 851 and CD206⁺IL-4R α ⁻Fizz1⁻ macrophages, and IL-4R α fluorescent intensity (arbitrary units [a.u.]) 852 n=5-8/group. DAPI (blue) was used to label nuclei. Red arrows indicate CD206⁺IL-4Ra⁻Fizz1⁻ 853 cells and vellow arrows indicate CD206⁺IL-4Rα⁺Fizz1⁺ cells. Statistics: 2-way ANOVA followed 854 by Tukey's multiple comparison test, except 1-way ANOVA followed by Tukey's multiple 855 comparison test in panel **C**; *p<0.05, **p<0.01 vs. Ctrl in **C**; **p<0.01 vs. Ctrl-scramble siRNA, 856 ^{##}p<0.01 vs. rmFIZZ1-scramble siRNA in **D.** N=6 per group. MM, mismatched; ASO, antisense 857 858 oligonucleotide.

Figure 8. Alternatively activated cardiac macrophages expand, express IL-4R α and 859 FIZZ3, and directly correlate with fibrosis in human heart failure (HF). A. Representative 860 flow plots for CD45⁺Autofluorescence(Auto)⁺CD64⁺CD206⁺ macrophages and their CCR2 861 expression, and group quantitation for CD206⁺ macrophages in normal control (Ctrl: n=3) and 862 failing (n=13) human hearts (from LV assist device core tissue). B, Representative trichrome 863 stains (Top) and low and high magnification (immuno)stains for CD163 (red) and collagen-864 hybridizing peptide (CHP, green) (Bottom) of Ctrl and failing human hearts, with corresponding 865 quantitation of cardiac fibrosis (10 Ctrl, 19 failing hearts) and CHP-associated and -866 unassociated CD163⁺ macrophage frequency (n=7/group). C. Low and high magnification 867 confocal images of immunostains for CD163 (white), IL-4R α (red) and Fizz3 (green) in normal 868 (Ctrl; n=4) and failing (n=8) human hearts (HF), and quantitation of IL-4R α ⁺Fizz3⁺ and IL-869 4Ra⁻Fizz3⁻ CD163⁺ macrophages. DAPI (blue) was used to label nuclei. White arrows indicate 870 CD163⁺IL-4Rα⁻Fizz3⁻ cells, and vellow arrows indicate CD163⁺IL-4Rα⁺Fizz3⁺ cells. Also shown 871 is the correlation between CD163⁺ macrophage abundance and LV fibrosis in human HF, n=19. 872 Statistics: Mann-Whitney test in A; unpaired Student's t test in **B-C**; Pearson R correlation test 873 in C, lower right panel. 874

875 **REFERENCES**

- 8761.Adamo L, Rocha-Resende C, Prabhu SD, Mann DL. Reappraising the role of877inflammation in heart failure. Nat Rev Cardiol. 2020;17:269-285. doi: 10.1038/s41569-878019-0315-x
- Bajpai G, Schneider C, Wong N, Bredemeyer A, Hulsmans M, Nahrendorf M, Epelman S, Kreisel D, Liu Y, Itoh A, et al. The human heart contains distinct macrophage subsets with divergent origins and functions. *Nat Med.* 2018;24:1234-1245. doi: 10.1038/s41591-018-0059-x
- Heidt T, Courties G, Dutta P, Sager HB, Sebas M, Iwamoto Y, Sun Y, Da Silva N,
 Panizzi P, van der Laan AM, et al. Differential contribution of monocytes to heart
 macrophages in steady-state and after myocardial infarction. *Circ Res.* 2014;115:284 295. doi: 10.1161/CIRCRESAHA.115.303567
- 4. Ismahil MA, Hamid T, Bansal SS, Patel B, Kingery JR, Prabhu SD. Remodeling of the mononuclear phagocyte network underlies chronic inflammation and disease progression in heart failure: critical importance of the cardiosplenic axis. *Circ Res.* 2014;114:266-282. doi: 10.1161/CIRCRESAHA.113.301720
- Sager HB, Hulsmans M, Lavine KJ, Moreira MB, Heidt T, Courties G, Sun Y, Iwamoto Y, Tricot B, Khan OF, et al. Proliferation and Recruitment Contribute to Myocardial Macrophage Expansion in Chronic Heart Failure. *Circ Res.* 2016;119:853-864. doi: 10.1161/CIRCRESAHA.116.309001
- Biggin Biggin
- Epelman S, Lavine KJ, Beaudin AE, Sojka DK, Carrero JA, Calderon B, Brija T, Gautier
 EL, Ivanov S, Satpathy AT, et al. Embryonic and adult-derived resident cardiac
 macrophages are maintained through distinct mechanisms at steady state and during
 inflammation. *Immunity*. 2014;40:91-104. doi: 10.1016/j.immuni.2013.11.019
- B. Lavine KJ, Epelman S, Uchida K, Weber KJ, Nichols CG, Schilling JD, Ornitz DM, Randolph GJ, Mann DL. Distinct macrophage lineages contribute to disparate patterns of cardiac recovery and remodeling in the neonatal and adult heart. *Proc Natl Acad Sci U S A*. 2014;111:16029-16034. doi: 10.1073/pnas.1406508111
- Bajpai G, Bredemeyer A, Li W, Zaitsev K, Koenig AL, Lokshina I, Mohan J, Ivey B, Hsiao
 HM, Weinheimer C, et al. Tissue Resident CCR2- and CCR2+ Cardiac Macrophages
 Differentially Orchestrate Monocyte Recruitment and Fate Specification Following
 Myocardial Injury. *Circ Res.* 2019;124:263-278. doi: 10.1161/CIRCRESAHA.118.314028
- Hilgendorf I, Gerhardt LM, Tan TC, Winter C, Holderried TA, Chousterman BG, Iwamoto
 Y, Liao R, Zirlik A, Scherer-Crosbie M, et al. Ly-6Chigh monocytes depend on Nr4a1 to
 balance both inflammatory and reparative phases in the infarcted myocardium. *Circ Res.* 2014;114:1611-1622. doi: 10.1161/CIRCRESAHA.114.303204
- 91511.Prabhu SD, Frangogiannis NG. The Biological Basis for Cardiac Repair After Myocardial916Infarction: From Inflammation to Fibrosis. Circ Res. 2016;119:91-112. doi:91710.1161/CIRCRESAHA.116.303577
- Prabhu SD. The Cardiosplenic Axis Is Essential for the Pathogenesis of Ischemic Heart
 Failure. *Trans Am Clin Climatol Assoc.* 2018;129:202-214.
- 92013.Revelo XS, Parthiban P, Chen C, Barrow F, Fredrickson G, Wang H, Yucel D, Herman A,921van Berlo JH. Cardiac Resident Macrophages Prevent Fibrosis and Stimulate922Angiogenesis. Circ Res. 2021;129:1086-1101. doi: 10.1161/CIRCRESAHA.121.319737
- Martini E, Kunderfranco P, Peano C, Carullo P, Cremonesi M, Schorn T, Carriero R,
 Termanini A, Colombo FS, Jachetti E, et al. Single-Cell Sequencing of Mouse Heart

925Immune Infiltrate in Pressure Overload-Driven Heart Failure Reveals Extent of Immune926Activation.Circulation.2019;140:2089-2107.doi:92710.1161/CIRCULATIONAHA.119.041694

- 15. Shiraishi M, Shintani Y, Shintani Y, Ishida H, Saba R, Yamaguchi A, Adachi H, Yashiro
 K, Suzuki K. Alternatively activated macrophages determine repair of the infarcted adult
 murine heart. *J Clin Invest.* 2016;126:2151-2166. doi: 10.1172/JCI85782
- 93116.Yan X, Anzai A, Katsumata Y, Matsuhashi T, Ito K, Endo J, Yamamoto T, Takeshima A,932933Shinmura K, Shen W, et al. Temporal dynamics of cardiac immune cell accumulation933following acute myocardial infarction. J Mol Cell Cardiol. 2013;62:24-35. doi:93410.1016/j.yjmcc.2013.04.023
- 17. Leblond AL, Klinkert K, Martin K, Turner EC, Kumar AH, Browne T, Caplice NM.
 936 Systemic and Cardiac Depletion of M2 Macrophage through CSF-1R Signaling Inhibition
 937 Alters Cardiac Function Post Myocardial Infarction. *PLoS One*. 2015;10:e0137515. doi:
 938 10.1371/journal.pone.0137515
- 939 18. Gordon S, Martinez FO. Alternative activation of macrophages: mechanism and 940 functions. *Immunity*. 2010;32:593-604. doi: 10.1016/j.immuni.2010.05.007
- 94119.Martinez FO, Gordon S. The M1 and M2 paradigm of macrophage activation: time for942reassessment. *F1000Prime Rep.* 2014;6:13. doi: 10.12703/P6-13
- 94320.Murray PJ, Allen JE, Biswas SK, Fisher EA, Gilroy DW, Goerdt S, Gordon S, Hamilton944JA, Ivashkiv LB, Lawrence T, et al. Macrophage activation and polarization:945nomenclature and experimental guidelines. Immunity. 2014;41:14-20. doi:94610.1016/j.immuni.2014.06.008
- Wynn TÅ, Vannella KM. Macrophages in Tissue Repair, Regeneration, and Fibrosis.
 Immunity. 2016;44:450-462. doi: 10.1016/j.immuni.2016.02.015
- 949 22. Tugal D, Liao X, Jain MK. Transcriptional control of macrophage polarization. 950 Arterioscler Thromb Vasc Biol. 2013;33:1135-1144. doi: 10.1161/ATVBAHA.113.301453
- 95123.Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine system952in diverse forms of macrophage activation and polarization. Trends Immunol.9532004;25:677-686. doi: 10.1016/j.it.2004.09.015
- Shintani Y, Ito T, Fields L, Shiraishi M, Ichihara Y, Sato N, Podaru M, Kainuma S, Tanaka H, Suzuki K. IL-4 as a Repurposed Biological Drug for Myocardial Infarction through Augmentation of Reparative Cardiac Macrophages: Proof-of-Concept Data in Mice. *Sci Rep.* 2017;7:6877. doi: 10.1038/s41598-017-07328-z
- 95825.Tang PM, Nikolic-Paterson DJ, Lan HY. Macrophages: versatile players in renal959inflammation and fibrosis. Nat Rev Nephrol. 2019;15:144-158. doi: 10.1038/s41581-019-9600110-2
- Bansal SS, Ismahil MA, Goel M, Patel B, Hamid T, Rokosh G, Prabhu SD. Activated T
 Lymphocytes are Essential Drivers of Pathological Remodeling in Ischemic Heart Failure.
 Circ Heart Fail. 2017;10:e003688. doi: 10.1161/CIRCHEARTFAILURE.116.003688
- Herbert DR, Holscher C, Mohrs M, Arendse B, Schwegmann A, Radwanska M, Leeto M,
 Kirsch R, Hall P, Mossmann H, et al. Alternative macrophage activation is essential for
 survival during schistosomiasis and downmodulates T helper 1 responses and
 immunopathology. *Immunity*. 2004;20:623-635. doi: 10.1016/s1074-7613(04)00107-4
- 96828.Vishlaghi N, Guo L, Griswold-Wheeler D, Sun Y, Booker C, Crossley JL, Bancroft AC,969Juan C, Korlakunta S, Ramesh S, et al. Vegfc-expressing cells form heterotopic bone970after musculoskeletal injury.Cell Rep.2024;43:114049.97110.1016/j.celrep.2024.114049
- Bansal SS, Ismahil MA, Goel M, Zhou G, Rokosh G, Hamid T, Prabhu SD. Dysfunctional and Proinflammatory Regulatory T-Lymphocytes Are Essential for Adverse Cardiac Remodeling in Ischemic Cardiomyopathy. *Circulation*. 2019;139:206-221. doi: 10.1161/CIRCULATIONAHA.118.036065

- Hamid T, Gu Y, Ortines RV, Bhattacharya C, Wang G, Xuan YT, Prabhu SD. Divergent
 tumor necrosis factor receptor-related remodeling responses in heart failure: role of
 nuclear factor-kappaB and inflammatory activation. *Circulation*. 2009;119:1386-1397. doi:
 10.1161/CIRCULATIONAHA.108.802918
- 98031.Wang G, Hamid T, Keith RJ, Zhou G, Partridge CR, Xiang X, Kingery JR, Lewis RK, Li Q,981Rokosh DG, et al. Cardioprotective and antiapoptotic effects of heme oxygenase-1 in the982failingheart.98310.1161/CIRCULATIONAHA.109.905471
- 98432.Patel B, Bansal SS, Ismahil MA, Hamid T, Rokosh G, Mack M, Prabhu SD. CCR2(+)985Monocyte-Derived Infiltrating Macrophages Are Required for Adverse Cardiac986Remodeling During Pressure Overload. JACC Basic Transl Sci. 2018;3:230-244. doi:98710.1016/j.jacbts.2017.12.006
- 33. Hamid T, Xu Y, Ismahil MA, Rokosh G, Jinno M, Zhou G, Wang Q, Prabhu SD. Cardiac 988 Mesenchymal Stem Cells Promote Fibrosis and Remodeling in Heart Failure: Role of 989 Transl PDGF Signaling. JACC Basic Sci. 2022;7:465-483. doi: 990 10.1016/j.jacbts.2022.01.004 991
- Wang Q, Wang S, Sun Z. Kidney-Specific Klotho Gene Deletion Causes Aortic
 Aneurysm via Hyperphosphatemia. *Hypertension*. 2021;78:308-319. doi:
 10.1161/HYPERTENSIONAHA.121.17299
- 35. Tang L, Zhang H, Wang C, Li H, Zhang Q, Bai J. M2A and M2C Macrophage Subsets
 Ameliorate Inflammation and Fibroproliferation in Acute Lung Injury Through Interleukin
 10 Pathway. *Shock.* 2017;48:119-129. doi: 10.1097/SHK.0000000000820
- Hamid T, Xu Y, Ismahil MA, Li Q, Jones SP, Bhatnagar A, Bolli R, Prabhu SD. TNF
 receptor signaling inhibits cardiomyogenic differentiation of cardiac stem cells and
 promotes a neuroadrenergic-like fate. *Am J Physiol Heart Circ Physiol*. 2016;311:H1189H1201. doi: 10.1152/ajpheart.00904.2015
- 37. Bujak M, Ratkaj I, Markova-Car E, Jurisic D, Horvatic A, Vucinic S, Lerga J, Baus-Loncar
 M, Pavelic K, Kraljevic Pavelic S. Inflammatory Gene Expression Upon TGF-beta1Induced p38 Activation in Primary Dupuytren's Disease Fibroblasts. *Front Mol Biosci.*2015;2:68. doi: 10.3389/fmolb.2015.00068
- 1006 38. Covarrubias R, Ismahil MA, Rokosh G, Hamid T, Accornero F, Singh H, Gumina RJ,
 1007 Prabhu SD, Bansal SS. Optimized protocols for isolation, fixation, and flow cytometric
 1008 characterization of leukocytes in ischemic hearts. *Am J Physiol Heart Circ Physiol.*1009 2019;317:H658-H666. doi: 10.1152/ajpheart.00137.2019
- 1010 39. Trouplin V, Boucherit N, Gorvel L, Conti F, Mottola G, Ghigo E. Bone marrow-derived 1011 macrophage production. *J Vis Exp.* 2013:e50966. doi: 10.3791/50966
- 101240.Ripple MJ, You D, Honnegowda S, Giaimo JD, Sewell AB, Becnel DM, Cormier SA.1013Immunomodulation with IL-4R alpha antisense oligonucleotide prevents respiratory1014syncytial virus-mediated pulmonary disease. J Immunol. 2010;185:4804-4811. doi:101510.4049/jimmunol.1000484
- Weng SY, Wang X, Vijayan S, Tang Y, Kim YO, Padberg K, Regen T, Molokanova O, Chen T, Bopp T, et al. IL-4 Receptor Alpha Signaling through Macrophages Differentially Regulates Liver Fibrosis Progression and Reversal. *EBioMedicine*. 2018;29:92-103. doi: 10.1016/j.ebiom.2018.01.028
- Nahrendorf M, Swirski FK, Aikawa E, Stangenberg L, Wurdinger T, Figueiredo JL, Libby
 P, Weissleder R, Pittet MJ. The healing myocardium sequentially mobilizes two
 monocyte subsets with divergent and complementary functions. *J Exp Med.* 2007;204:3037-3047. doi: 10.1084/jem.20070885
- 102443.Bakhshian Nik A, Alvarez-Argote S, O'Meara CC. Interleukin 4/13 signaling in cardiac1025regeneration and repair. Am J Physiol Heart Circ Physiol. 2022;323:H833-H844. doi:102610.1152/ajpheart.00310.2022

- 102744.Shankar A, McAlees JW, Lewkowich IP. Modulation of IL-4/IL-13 cytokine signaling in1028the context of allergic disease. J Allergy Clin Immunol. 2022;150:266-276. doi:102910.1016/j.jaci.2022.06.012
- 103045.Junttila IS. Tuning the Cytokine Responses: An Update on Interleukin (IL)-4 and IL-131031Receptor Complexes. Front Immunol. 2018;9:888. doi: 10.3389/fimmu.2018.00888
- Krawiec P, Pawlowska-Kamieniak A, Pac-Kozuchowska E. Interleukin 10 and interleukin
 10 receptor in paediatric inflammatory bowel disease: from bench to bedside lesson. J
 Inflamm (Lond). 2021;18:13. doi: 10.1186/s12950-021-00279-3
- 103547.Walter MR. The molecular basis of IL-10 function: from receptor structure to the onset of1036signaling. Curr Top Microbiol Immunol. 2014;380:191-212. doi: 10.1007/978-3-662-103743492-5_9
- 48. Jones B, Debski A, Hans CP, Go MR, Agarwal G. Structurally abnormal collagen fibrils
 in abdominal aortic aneurysm resist platelet adhesion. *J Thromb Haemost*. 2022;20:470477. doi: 10.1111/jth.15576
- 104149.Cao Q, Wang Y, Zheng D, Sun Y, Wang Y, Lee VW, Zheng G, Tan TK, Ince J,1042Alexander SI, et al. IL-10/TGF-beta-modified macrophages induce regulatory T cells and1043protect against adriamycin nephrosis. J Am Soc Nephrol. 2010;21:933-942. doi:104410.1681/ASN.2009060592
- 104550.Roszer T. Understanding the Mysterious M2 Macrophage through Activation Markers1046and Effector Mechanisms. Mediators Inflamm. 2015;2015:816460. doi:104710.1155/2015/816460
- 104851.Nair MG, Du Y, Perrigoue JG, Zaph C, Taylor JJ, Goldschmidt M, Swain GP,1049Yancopoulos GD, Valenzuela DM, Murphy A, et al. Alternatively activated macrophage-1050derived RELM-{alpha} is a negative regulator of type 2 inflammation in the lung. J Exp1051Med. 2009;206:937-952. doi: 10.1084/jem.20082048
- 1052 52. Nair MG, Gallagher IJ, Taylor MD, Loke P, Coulson PS, Wilson RA, Maizels RM, Allen
 1053 JE. Chitinase and Fizz family members are a generalized feature of nematode infection
 1054 with selective upregulation of Ym1 and Fizz1 by antigen-presenting cells. *Infect Immun.*1055 2005;73:385-394. doi: 10.1128/IAI.73.1.385-394.2005
- 105653.Liu T, Hu B, Choi YY, Chung M, Ullenbruch M, Yu H, Lowe JB, Phan SH. Notch11057signaling in FIZZ1 induction of myofibroblast differentiation. Am J Pathol.10582009;174:1745-1755. doi: 10.2353/ajpath.2009.080618
- 105954.Liu T, Yu H, Ullenbruch M, Jin H, Ito T, Wu Z, Liu J, Phan SH. The in vivo fibrotic role of1060FIZZ1inpulmonaryfibrosis.PLoSOne.2014;9:e88362.doi:106110.1371/journal.pone.0088362
- 106255.Jenkins SJ, Ruckerl D, Thomas GD, Hewitson JP, Duncan S, Brombacher F, Maizels1063RM, Hume DA, Allen JE. IL-4 directly signals tissue-resident macrophages to proliferate1064beyond homeostatic levels controlled by CSF-1. J Exp Med. 2013;210:2477-2491. doi:106510.1084/jem.20121999
- 106656.Rizzo P, Miele L, Ferrari R. The Notch pathway: a crossroad between the life and death1067of the endothelium. *Eur Heart J.* 2013;34:2504-2509. doi: 10.1093/eurheartj/ehs141
- 106857.Talele NP, Fradette J, Davies JE, Kapus A, Hinz B. Expression of alpha-Smooth Muscle1069Actin Determines the Fate of Mesenchymal Stromal Cells. Stem Cell Reports.10702015;4:1016-1030. doi: 10.1016/j.stemcr.2015.05.004
- 107158.Lurier EB, Dalton D, Dampier W, Raman P, Nassiri S, Ferraro NM, Rajagopalan R,1072Sarmady M, Spiller KL. Transcriptome analysis of IL-10-stimulated (M2c) macrophages1073by next-generation sequencing. Immunobiology. 2017;222:847-856. doi:107410.1016/j.imbio.2017.02.006
- 107559.Pine GM, Batugedara HM, Nair MG. Here, there and everywhere: Resistin-like1076molecules in infection, inflammation, and metabolic disorders. *Cytokine*. 2018;110:442-1077451. doi: 10.1016/j.cyto.2018.05.014

- 107860.Etzerodt A, Moestrup SK. CD163 and inflammation: biological, diagnostic, and1079therapeutic aspects. Antioxid Redox Signal. 2013;18:2352-2363. doi:108010.1089/ars.2012.4834
- 1081
 61.
 Frangogiannis
 NG.
 Cardiac
 fibrosis.
 Cardiovasc
 Res.
 2021;117:1450-1488.
 doi:

 1082
 10.1093/cvr/cvaa324
- Pechkovsky DV, Prasse A, Kollert F, Engel KM, Dentler J, Luttmann W, Friedrich K,
 Muller-Quernheim J, Zissel G. Alternatively activated alveolar macrophages in pulmonary fibrosis-mediator production and intracellular signal transduction. *Clin Immunol.* 2010;137:89-101. doi: 10.1016/j.clim.2010.06.017
- 1087 63. Wang J, Xu L, Xiang Z, Ren Y, Zheng X, Zhao Q, Zhou Q, Zhou Y, Xu L, Wang Y.
 1088 Microcystin-LR ameliorates pulmonary fibrosis via modulating CD206(+) M2-like
 1089 macrophage polarization. *Cell Death Dis*. 2020;11:136. doi: 10.1038/s41419-020-2329-z
- 109064.Carlson S, Helterline D, Asbe L, Dupras S, Minami E, Farris S, Stempien-Otero A.1091Cardiac macrophages adopt profibrotic/M2 phenotype in infarcted hearts: Role of1092urokinase plasminogen activator. J Mol Cell Cardiol. 2017;108:42-49. doi:109310.1016/j.yjmcc.2016.05.016
- 1094 65. Sieweke MH, Allen JE. Beyond stem cells: self-renewal of differentiated macrophages. 1095 *Science*. 2013;342:1242974. doi: 10.1126/science.1242974
- Martinez FO, Helming L, Milde R, Varin A, Melgert BN, Draijer C, Thomas B, Fabbri M, Crawshaw A, Ho LP, et al. Genetic programs expressed in resting and IL-4 alternatively activated mouse and human macrophages: similarities and differences. *Blood*.
 2013;121:e57-69. doi: 10.1182/blood-2012-06-436212
- 110067.Kim JE, Jung K, Kim JA, Kim SH, Park HS, Kim YS. Engineering of anti-human1101interleukin-4 receptor alpha antibodies with potent antagonistic activity. Sci Rep.11022019;9:7772. doi: 10.1038/s41598-019-44253-9
- Holcomb IN, Kabakoff RC, Chan B, Baker TW, Gurney A, Henzel W, Nelson C, Lowman HB, Wright BD, Skelton NJ, et al. FIZZ1, a novel cysteine-rich secreted protein associated with pulmonary inflammation, defines a new gene family. *EMBO J.* 2000;19:4046-4055. doi: 10.1093/emboj/19.15.4046
- 110769.Chemaly ER, Hadri L, Zhang S, Kim M, Kohlbrenner E, Sheng J, Liang L, Chen J, P KR,1108Hajjar RJ, et al. Long-term in vivo resistin overexpression induces myocardial1109dysfunction and remodeling in rats. J Mol Cell Cardiol. 2011;51:144-155. doi:111010.1016/j.yjmcc.2011.04.006
- Takeishi Y, Niizeki T, Arimoto T, Nozaki N, Hirono O, Nitobe J, Watanabe T, Takabatake
 N, Kubota I. Serum resistin is associated with high risk in patients with congestive heart
 failure--a novel link between metabolic signals and heart failure. *Circ J.* 2007;71:460-464.
 doi: 10.1253/circj.71.460















